Page last updated: 2024-12-08

deoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID222528
CHEMBL ID406393
CHEBI ID28834
SCHEMBL ID4300
MeSH IDM0005992

Synonyms (163)

Synonym
MLS001066423
smr000112166
BIDD:PXR0198
CHEBI:28834 ,
desoxycholsaeure
gtpl610
NCI60_041946
hsdb 293
nsc 8797
einecs 201-478-5
brn 3219882
ccris 1627
cholorebic
desoxycholic acid
3.alpha.,12.alpha.-dihydroxy-5.beta.-cholanoic acid
3.alpha.,12.alpha.-dihydroxycholanic acid
cholan-24-oic acid,12-dihydroxy-, (3.alpha.,5.beta.,12.alpha.)-
deoxycholatic acid
5.beta.-cholan-24-oic acid,12.alpha.-dihydroxy-
choleic acid
3.alpha.,12.alpha.-dihydroxy-5.beta.-cholanic acid
septochol
nsc8797 ,
degalol
cholerebic
7.alpha.-deoxycholic acid
droxolan
3,12-dihydroxycholanic acid
3.alpha.,12.alpha.-dihydroxy-5.beta.-cholan-24-oic acid
cholic acid, deoxy-
pyrochol
nsc-8797
17.beta.-(1-methyl-3-carboxypropyl)-etiocholane-3.alpha.,12.alpha.-diol
kybella
SPECTRUM5_002007
cholan-24-oic, 3,12-dihydroxy-(3alpha,5beta,12alpha)-
5-beta-deoxycholic acid
desoxycholsaeure [german]
(3alpha,5beta,12alpha)-3,12-dihydroxycholan-24-oic acid
cholan-24-oic acid, 3,12-dihydroxy-, (3alpha,5beta,12alpha)-
3-alpha,12-alpha-dihydroxy-5-beta-cholanoic acid
DXC ,
3-alpha,12-alpha-dihydroxycholansaeure [german]
deoxy cholic acid
dihydroxycholanoic acid
3,12-dihydroxycholan-24-oic acid, (3alpha,5beta,12alpha)-
cholan-24-oic acid, 3,12-dihydroxy-, (3-alpha,5-beta,12-alpha)-
17-beta-(1-methyl-3-carboxypropyl)-etiocholane-3-alpha,12-alpha-diol
5-beta-cholan-24-oic acid, 3-alpha,12-alpha-dihydroxy-
3-alpha,12-alpha-dihydroxy-5-beta-cholan-24-oic acid
l7-beta-(1-methyl-3-carboxypropyl)-etiocholane-3-alpha,12-alpha-diol
7alpha-deoxycholic acid
5beta-cholan-24-oic acid, 3alpha,12alpha-dihydroxy-
3alpha,12alpha-dihydroxy-5beta-cholan-24-oic acid
deoxycholic acid
C04483
deoxycholate ,
83-44-3
3alpha,12alpha-dihydroxy-5beta-cholanic acid
(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
cholan-24-oic acid, 3,12-dihydroxy-, (3-.alpha., 5-.beta.,12-.alpha.)-
deoxycholic acid, >=98% (hplc)
deoxycholic acid, bioxtra, >=98% (hplc)
1E3V
DB03619
LMST04010040
MLS001306460
7-deoxycholic acid
atx-101 (deoxycholic acid)
CHEMBL406393
dwj211
dwj-211
atx-101
STK801948
BBL013877
AKOS005622617
BMSE000833
HMS2270H22
atx 101
S4689
bdbm50375599
(r)-4-((3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
unii-005990whzz
atx101
deoxycholic acid [usan:inn]
005990whzz ,
3-alpha,12-alpha-dihydroxycholansaeure
desoxycholic acid [nf]
4-10-00-01608 (beilstein handbook reference)
BP-13275
deoxycholic acid [who-dd]
deoxycholic acid [inn]
deoxycholic acid [usan]
deoxycholic acid [ii]
desoxycholic acid [fcc]
deoxycholic acid [hsdb]
desoxycholic acid [vandf]
deoxycholic acid [mi]
deoxycholic acid [usp monograph]
deoxycholic acid [inci]
deoxycholic acid [orange book]
ursodeoxycholic acid impurity e [ep impurity]
deoxycholic acid [ep impurity]
deoxycholic acid [usp-rs]
SCHEMBL4300
DTXSID0042662 ,
de-oxycholate
3alpha,12alpha-dihydroxycholanic acid
l7-.beta.-(1-methyl-3-carboxypropyl)-etiocholane-3-.alpha.,12-.alpha.-diol
3-.alpha.,12-.alpha.-dihydroxycholansaeure
5.beta.-cholan-24-oic acid, 3.alpha.,12.alpha.-dihydroxy-
3,12-dihydroxycholan-24-oic acid, (3.alpha.,5.beta.,12.alpha.)- #
7-desoxycholic acid
cholan-24-oic acid, 3,12-dihydroxy-, (3a,5b,12a)-
CS-7613
mfcd00003673
kybella (tn)
deoxycholic acid (nf/inn)
D10781
SR-01000765601-2
sr-01000765601
deoxycholic acid, >=99.0% (t)
deoxycholic acid, 500 mug/ml in methanol, certified reference material
deoxycholic acid (desoxycholic acid), united states pharmacopeia (usp) reference standard
desoxycholsaure
deoxycholatate
7-deoxycholate
deoxy-cholate
deoxy-cholic acid
5b-deoxycholate
5b-deoxycholic acid
5b-cholanic acid-3a,12a-diol
HY-N0593
(3alpha,5alpha,8alpha,12alpha,14beta,17alpha)-3,12-dihydroxycholan-24-oic acid
Q425680
3i+/-,12i+/--dihydroxy-5i(2)-cholansa currencyure
AS-13233
cholanoic acid;desoxycholic acid
(4r)-4-((3r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(4r)-4-[(1r,3as,3br,5ar,7r,9as,9bs,11s,11ar)-7,11-dihydroxy-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-1-yl]pentanoic acid
EN300-108204
deoxycholic-acid
CCG-268565
3alpha
D85117
3alpha,12alpha-dihydroxy-5beta-cholan-24-oic acid (deoxycholic acid)
Z1416203075
acidum deoxycholicum
17-beta-(1-methyl-3-carboxypropyl)-etiocholane-3-alpha, 12-alpha-diol
(4r)-4-((3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta(a)phenanthren-17-yl)pentanoic acid
deoxycholic acid (usp-rs)
acido desoxicolico
ursodeoxycholic acid impurity e (ep impurity)
cholan-24-oic, 3,12-dihydroxy-(3alpha,5beta, 12alpha)-
3alpha,12alpha-dihydroxy-5beta-cholanoic acid
deoxycholic acid (ii)
deoxycholic acid (usp monograph)
d11ax24
dtxcid8022662
(3alpha,5beta,12alpha)-3,12-dihydroxycholan-oic acid
deoxycholic acidc
deoxycholic acid (ep impurity)
acide desoxycholique

Research Excerpts

Overview

Deoxycholic acid (DCA) 1% is an injectable detergent indicated for submental fat reduction, although clinically it is being injected off-label for orbital fat prolapse. Hyodeoxycholics acid (HDCA) is a natural secondary bile acid with enormous pharmacological effects, such as modulating inflammation in neuron.

ExcerptReferenceRelevance
"Deoxycholic acid (DCA) is a major active constituent of Niuhuang."( Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants.
Chen, X; Dong, H; Howard, OM; Mellon, RD; Oppenheim, JJ; Yang, L, 2002
)
1.35
"Deoxycholic acid is an FDA-approved injectable for treatment of excess submental fat."( Safety and Efficacy of Deoxycholic Acid for Reduction of Upper Inner Thigh Fat.
Ortiz, A; Shafiq, F; Yuan, J, 2022
)
2.47
"Deoxycholic Acid (DCA), which is an FDA-approved compound for the reduction of submental fat, has evolved through an unanticipated and surprising sequence of events. "( The Role of Fat Reducing Agents on Adipocyte Death and Adipose Tissue Inflammation.
Kost, Y; McLellan, BN; Muskat, A; Pirtle, M; Shinoda, K, 2022
)
2.16
"Hyodeoxycholic acid (HDCA) is a natural secondary bile acid with enormous pharmacological effects, such as modulating inflammation in neuron. "( Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5/AKT/NF-κB signaling pathway.
Bai, Y; Huang, F; Shi, H; Su, Y; Tao, Y; Wang, G; Wang, L; Wu, H; Wu, X; Yang, L; Zhu, H, 2022
)
1.96
"Deoxycholic acid (ATX-101) is a secondary bile acid that was approved as an injectable drug for the reduction of submental fat. "( Inadvertent intra-arterial injection of deoxycholic acid: A case report and proposed protocol for treatment.
Lindgren, AL; Welsh, KM, 2020
)
2.27
"Deoxycholic acid (DCA) 1% is an injectable detergent indicated for submental fat reduction, although clinically it is being injected off-label for orbital fat prolapse. "( Orbital Hemorrhagic Necrosis, Globe Rupture, and Death From Intraorbital Injection of 1% Sodium Deoxycholate in a Murine Model.
Blessing, NW; Chen, Y; Choi, CJ; Kanokkantapong, J; Lee, BW; Pelaez, D; Tao, W,
)
1.57
"Deoxycholic acid is an endogenous secondary bile acid that normally solubilizes dietary fat, contributing to its breakdown and absorption within the gut."( The development, evidence, and current use of ATX-101 for the treatment of submental fat.
Georgesen, C; Lipner, SR, 2017
)
1.18
"Deoxycholic acid (DCA) is a secondary bile acid implicated in various cancers of the gastrointestinal (GI) tract. "( The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.
Alhamdani, A; Baxter, JN; Cronin, J; D'Souza, F; Eltahir, Z; Griffiths, AP; Jenkins, GJ; Rawat, N; Thomas, T, 2008
)
2.15
"Deoxycholic acid (DCA) is a secondary bile acid that modulates signalling pathways in epithelial cells. "( Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells.
Byrne, AM; Davies, A; Foran, E; Kelleher, D; Long, A; Mahon, C; O'Donoghue, D; O'Sullivan, J; Sharma, R, 2010
)
1.8
"Deoxycholic acid (DCA) is a known hepatotoxicant, a tissue tumor promoter, and has been implicated in colorectal cancer. "( Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability.
Csanaky, IL; Klaassen, CD; Lehman-McKeeman, LD; Zhang, Y, 2011
)
2.05
"Deoxycholic acid (DOCA) is a bile acid that facilitates the gastrointestinal (GI) absorption of low molecular weight heparin (LMWH) by bonding chemically to it. "( Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Byun, Y; Kim, CY; Kim, SK; Lee, DY; Lee, S; Lee, YK; Moon, HT; Shin, HC, 2006
)
2
"Deoxycholic acid (DCA) is an endogenous secondary bile acid implicated in numerous pathological conditions including colon cancer formation and progression and cholestatic liver disease. "( Enantiomeric deoxycholic acid: total synthesis, characterization, and preliminary toxicity toward colon cancer cell lines.
Anant, S; Covey, DF; Katona, BW; Rath, NP; Stenson, WF, 2007
)
2.15
"Deoxycholic acid is a microbial product of cholic acid 7alpha-dehydroxylation in the intestines."( Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients.
Berr, F; Dowling, RH; Hylemon, PB; Thomas, LA; Wells, JE, 2000
)
1.03
"Chenodeoxycholic acid (CDCA) is a potent suppressor of the cholesterol 7alpha-hydroxylase, the rate-determining enzyme in bile acid formation."( Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects.
Axelson, M; Einarsson, C; Hillebrant, CG, 2001
)
1.07
"Chenodeoxycholic acid is an important drug for the treatment of cholesterol cholelithiasis in man. "( Toxicity of chenodeoxycholic acid in the rhesus monkey.
Chen, T; Dyrszka, H; Mosbach, EH; Salen, G, 1975
)
1.11
"Ursodeoxycholic acid (ursodiol) is an oral dissolution agent recently approved by the Food and Drug Administration for treatment of cholelithiasis. "( Medical management of gallstones: a cost-effectiveness analysis.
Coley, CM; Richter, JM; Weinstein, MC,
)
0.69
"Ursodeoxycholic acid (ursodiol) is a naturally occurring bile acid that constitutes about 1-2% of the bile acids in human bile. "( Clinical perspective on the treatment of gallstones with ursodeoxycholic acid.
Salen, G, 1988
)
1.07

Effects

Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit. has a malignancy-inducing effect on the transformation of esophageal adenocarcinoma stem cells. Ursodeoxycholics acid has been proposed for the treatment of primary biliary cirrhosis.

ExcerptReferenceRelevance
"Deoxycholic acid has a malignancy-inducing effect on the transformation of esophageal adenocarcinoma stem cells, improving the antiapoptotic ability of tumors, and increasing the malignancy of esophageal adenocarcinoma."( Deoxycholic Acid Upregulates the Reprogramming Factors KFL4 and OCT4 Through the IL-6/STAT3 Pathway in Esophageal Adenocarcinoma Cells.
Chen, M; Poon, K; Wang, R; Wei, J; Ye, A,
)
2.3
"Deoxycholic acid has a malignancy-inducing effect on the transformation of esophageal adenocarcinoma stem cells, improving the antiapoptotic ability of tumors, and increasing the malignancy of esophageal adenocarcinoma."( Deoxycholic Acid Upregulates the Reprogramming Factors KFL4 and OCT4 Through the IL-6/STAT3 Pathway in Esophageal Adenocarcinoma Cells.
Chen, M; Poon, K; Wang, R; Wei, J; Ye, A,
)
2.3
"Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit"( Eudragit
Al-Salami, H; Arfuso, F; Goločorbin-Kon, S; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N, 2018
)
1.92
"Deoxycholic acid (DCA) has been shown to promote proliferation of colonic carcinoma cells in many fundamental studies. "( Significance of fecal deoxycholic acid concentration for colorectal tumor enlargement.
Ishikawa, H; Kamano, T; Kanoh, M; Kawano, A; Kono, K; Nakamura, T; Otani, T; Sakai, T; Sakamoto, K, 2010
)
2.12
"Deoxycholic acid (DCA) has been appeared to be an endogenous colon tumor promoter. "( [Deoxycholic acid-induced signal transduction in HT-29 cells: role of NF-kappa B and interleukin-8].
Baik, SK; Chung, JM; Kim, HS; Kwon, SO; Lee, DK; Oh, ES; Park, SY, 2004
)
2.68
"Deoxycholic acid (DCA) has been implicated in colorectal carcinogenesis in humans with effects on proliferation and apoptosis, mediated at least in part by activation of transcription factors nuclear factor kappa B (NF-kappaB), activator protein 1 (AP-1) and protein kinase C (PKC) enzymes. "( Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells.
Abdel-Latif, MM; Arfin, Q; Kelleher, D; Shah, SA; Volkov, Y, 2006
)
2.33
"Deoxycholic acid (DCA) has been implicated in colonic carcinogenesis through effects mediated by protein kinase C (PKC) activation. "( Ursodeoxycholic acid inhibits translocation of protein kinase C in human colonic cancer cell lines.
Kelleher, D; Long, A; Looby, E; Shah, SA; Volkov, Y, 2005
)
2.33
"Ursodeoxycholic acid has been proposed for the treatment of primary biliary cirrhosis. "( Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.
Aldini, R; Bazzoli, F; Cipolla, A; Festi, D; Mazzella, G; Parini, P; Polimeni, C; Roda, A; Tonelli, D; Villanova, N, 1993
)
1.4
"Ursodeoxycholic acid has been shown to be useful in the treatment of cholestatic liver disease."( Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury.
Kobayashi, S; Kumai, T; Nakaya, S; Nakura, H; Tanaka, M; Tateishi, T; Watanabe, M, 1999
)
1.34
"Deoxycholic acid (DCA) has long been implicated as tumour-promoting agent in the colon. "( Low-dose deoxycholic acid stimulates putrescine uptake in colon cancer cells (Caco-2).
Gilani, S; Milovic, V; Murphy, GM; Odera, G; Stein, J, 2000
)
2.17
"Deoxycholic acid has long been attributed as a tumour promoter in the colon. "( Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation.
Caspary, WF; Faust, D; Milovic, V; Stein, J; Teller, IC, 2002
)
1.76
"Ursodeoxycholic acid (UDCA) has been used in the medical treatment of various gastrointestinal diseases. "( [Effect of ursodeoxycholic acid on water immersion restraint stress ulcer of rats].
Ishimori, A; Kawamura, T; Koizumi, F, 1989
)
1.19
"Ursodeoxycholic acid (ursodiol) has been shown to be an effective oral agent for dissolution of gallstones that also has a favorable safety profile. "( Gallstone dissolution therapy with ursodiol. Patient selection.
Fromm, H, 1989
)
0.84
"Ursodeoxycholic acid (UDCA) has been reported to improve liver function tests when administered to patients with cholestatic liver diseases, such as primary biliary cirrhosis (PBC). "( Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis.
Aldini, R; Bazzoli, F; Festi, D; Mazzella, G; Minutello, A; Poggi, C; Roda, E; Ronchi, M; Simoni, P; Villanova, N, 1989
)
1.2

Actions

ExcerptReferenceRelevance
"Deoxycholic acid (DCA) promotes the development and progression of esophageal adenocarcinoma (EAC) by inducing inflammation. "( Adiponectin modulates DCA-induced inflammation via the ROS/NF-κ B signaling pathway in esophageal adenocarcinoma cells.
Liu, D; Shakya, P; Shi, H; Wu, J; Yin, X; Zhang, J; Zhang, R, 2014
)
1.85

Treatment

Ursodeoxycholic acid treatment (600 mg/day) was evaluated in a patient with asymptomatic primary sclerosing cholangitis. Treatment did not adversely affect liver function tests, and alkaline phosphatase decreased.

ExcerptReferenceRelevance
"Ursodeoxycholic acid treatment did not adversely affect liver function tests, and alkaline phosphatase decreased."( Medical treatment of biliary duct stones: effect of ursodeoxycholic acid administration.
Lugli, R; Salati, R; Salvioli, G; Zanni, C, 1983
)
0.99
"Ursodeoxycholic acid treatment improved liver function tests; after 4 weeks glutamate dehydrogenase (GLDH) had decreased."( Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.
Bhatti, S; Güldütuna, S; Hübner, K; Leuschner, M; Leuschner, U; Nickel, A; Wunderlich, N, 1993
)
1.09
"Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity."( Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Angelin, B; Axelson, M; Björkhem, I; Einarsson, C; Hillebrant, C; Nyberg, B; Rudling, M, 1999
)
2.47
"Ursodeoxycholic acid treatment (600 mg/day) was evaluated in a patient with asymptomatic primary sclerosing cholangitis. "( Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid.
Hayashi, H; Higuchi, T; Hishida, N; Ichimiya, H; Sakamoto, N, 1990
)
1.08
"Ursodeoxycholic acid treatment of patients with primary biliary cirrhosis may lead to relief of pruritus and improvement of biochemical liver tests. "( Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.
Bircher, J; Endele, R; Fölsch, U; Hopf, U; Klaus, J; Lotterer, E; Möller, B; Raedsch, R; Rudolph, G; Stiehl, A, 1990
)
1.4
"Ursodeoxycholic acid treatment significantly (P less than 0.02) decreased the cholesterol saturation index (mean +/- S.E.: 0.94 +/- 0.05 vs."( Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones.
Brenner, G; Jüngst, D; Paumgartner, G; Pratschke, E, 1989
)
1.13

Toxicity

Deoxycholic acid may be a safe and effective option for reducing fat thickness in the hypogastric region, although given the cost/benefit ratio probably should be reserved for small deposits. The low to moderate certainty of evidence found allows concluding that deoxy cholic acid is effective in submental fat reduction.

ExcerptReferenceRelevance
"The influence of mixtures of taurocholate (TC), oleic acid (OA), caprylic acid (CA), and monolein (MO) on the toxic effects of deoxycholate (DC) in rat jejunum have been investigated using both a closed loop and perfusion technique."( Influence of mixtures of taurocholate, fatty acids, and monolein on the toxic effects of deoxycholate in rat jejunum in vivo.
Guiraldes, E; Harries, JT; Lamabadusuriya, SP, 1975
)
0.25
" Solutions in which AmB was almost entirely monomeric were half as toxic after 24 h and about six times less toxic after 1 week than the corresponding solutions of Fungizone."( Effects of the aggregation state of amphotericin B on its toxicity to mice.
Barwicz, J; Christian, S; Gruda, I, 1992
)
0.28
" Thus, ABCD shows promise as an effective but less toxic alternative to ABDS for the treatment of disseminated cryptococcosis."( Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.
Clemons, KV; Hanson, LH; Hostetler, JS; Stevens, DA, 1992
)
0.28
" AB and hypoxia/reoxygenation caused additive, not synergistic, LDH release whereas CS-AB had no adverse effect."( Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents.
Bredl, CR; Schimpf, BA; Zager, RA, 1992
)
0.28
" It is concluded that UDCA appears to be safe only in stages I to III and that prognostic stratification based on bile acid levels or on the histological stage of the disease should be an important aspect of controlled clinical trials."( Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.
Bircher, J; Foelsch, UR; Lotterer, E; Raedsch, R; Stiehl, A, 1990
)
0.84
" Overall, ursodiol is a safe and effective litholytic agent."( Gallstone dissolution therapy with ursodiol. Efficacy and safety.
Salen, G, 1989
)
0.28
" This study demonstrates DCA gastrotoxicity at concentrations comparable to human intragastric total bile acid concentrations and the suitability of this model for studying the toxic components of refluxed duodenal contents."( Is the ex vivo rat gastric chamber model suitable for studying the gastrotoxicity of refluxed duodenal contents? Initial results using deoxycholic acid.
Armstrong, D; Dowling, RH; Farrell, M; Hanby, A; Murphy, GM, 1988
)
0.48
" The findings suggest that the chenodeoxycholic-ursodeoxycholic acid combination provides a safe and efficacious treatment for some cholesterol gallstones."( Gallstone dissolution treatment with a combination of chenodeoxycholic and ursodeoxycholic acids. Studies of safety, efficacy and effects on bile lithogenicity, bile acid pool, and serum lipids.
Ceryak, S; Fromm, H; Malavolti, M; Roehrkasse, R; Tunuguntla, AK, 1986
)
0.75
" Thus, ursodeoxycholic acid appears to be a safe and effective alternative to surgery in selected patients with gallstones."( Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones.
Colalillo, A; Graber, D; Salen, G; Shefer, S; Speck, J; Tint, GS; Verga, D, 1982
)
1.21
" Furthermore, we observe that AmpB was less toxic in vitro to pig kidney cells when associated with HDL, but still toxic when associated with LDL."( Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
Lopez-Berestein, G; Morton, RE; Rosenblum, MG; Wasan, KM, 1994
)
0.29
"01) with the LD50 of AmB."( Influence of diet on experimental toxicity of amphotericin B deoxycholate.
Bolard, J; Carbon, C; Chavanet, P; Joly, V; Rigaud, D; Yeni, P, 1994
)
0.29
"Quantitative aspects of bile acid cytotoxicity to colon cancer cell lines were investigated because of the etiological role in colon carcinogenesis attributed to the toxic effects of bile acids on colon mucosal cells."( Toxicity of bile acids to colon cancer cell lines.
Fiander, H; Latta, RK; Ross, NW; Schneider, H; Simpson, C, 1993
)
0.29
" The coupling of cell colonies with a suitable transduction device has led to the development in recent years of toxicity biosensors based on the alteration of a process or a cell metabolic function by the toxic substance under examination."( Toxicity order of cholanic acids using an immobilised cell biosensor.
Campanella, L; Favero, G; Mastrofini, D; Tomassetti, M, 1996
)
0.29
"In previous work acute toxic effects of amphotericin B (AB) were reduced in both in vitro and in vivo tests when AB was associated with a triglyceride-rich emulsion (AB-emulsion)."( Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study.
Campa, A; Saldiva, PH; Souza, LC, 2000
)
0.31
"Nephrotoxicity is an important side effect of amphothericin B deoxycholate (ampho B) and cyclosporine A (CsA)."( Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation.
Furrer, K; Halter, J; Imhof, A; Schaffner, A; Schanz, U; Vavricka, SR, 2002
)
0.31
" Expensive lipid formulations of amphotericin B (AmB) are generally used because of fear of adverse effects due to concomitant cyclosporine A and other nephrotoxic drugs."( Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients.
Boehler, A; Dutly, A; Naef, R; Russi, EW; Speich, R; Weder, W, 2002
)
0.31
"Based on histologic data, increasing doses of all three agents appear to be associated with increasing toxicity, however based on ophthalmologic data, L-AmB appears to be less toxic than either amphotericin B deoxycholate or ABLC."( Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon, JP; Danziger, LH; De Alba, F; Edward, DP; Fiscella, R; Garey, KW; Pattharachayakul, S; Piscitelli, S, 2003
)
0.32
" Treatment-related adverse events and invasive fungal infections were quantitated for 2 months after study drug initiation."( Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
Benjamin, DK; Dodds Ashley, E; Drew, RH; Duane Davis, R; Palmer, SM; Perfect, JR, 2004
)
0.32
" Patients receiving ABLC were less likely to experience a treatment-related adverse event."( Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
Benjamin, DK; Dodds Ashley, E; Drew, RH; Duane Davis, R; Palmer, SM; Perfect, JR, 2004
)
0.32
" We conclude that continuous infusion of amphotericin B is safe in neutropenic patients with hematological malignancies."( Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies.
Knöbl, P; Rabitsch, W; Schulenburg, A; Sperr, W; Thalhammer, F, 2005
)
0.33
"Amphotericin B deoxycholate (AmBd) has been a standard therapy for IFI but is associated with high adverse event and mortality rates."( Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino, J; Lew, D; Markham, L; Matulionyte, R; Rives, V, 2006
)
0.33
" However, d-AMB is a toxic drug, the most important dose-limiting toxicities being nephrotoxicity and infusion-related allergic reactions."( Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Disel, U; Oto, OA; Paydas, S; Seydaoglu, G; Yavuz, S, 2007
)
0.34
"In lung transplant recipients, both inhaled AmBd and L-AmB were safe and well tolerated over a large number of medication exposures."( Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Baden, LR; Deykin, A; Fiumara, K; Lee, JT; Lowry, CM; Marty, FM; Vargas, SO, 2007
)
0.34
" These findings indicated that the oral anticoagulant drug, a newly developed oral heparin derivative, did not have any toxic effect for 2 week in this study."( Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys.
Byun, Y; Han, K; Kim, CY; Kim, J; Kim, S; Park, K, 2007
)
0.34
" But the need for prolonged hospitalisation and frequent, occasionally serious, adverse events are its major drawbacks."( Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Agarwal, D; Agrawal, N; Chakravarty, J; Rai, M; Shah, A; Sundar, S, 2008
)
0.35
"To evaluate medical indications of this compound in a tertiary care center, analyze adverse reactions, infusion protocols and outcome of treated patients."( [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Abusada A, N; Fica C, A; Gallardo A, C; Muñoz C, L; Novoa M, C; Quinteros A, R, 2010
)
0.36
"Retrospective analysis of 39 treatments indicated in 33 patients during 2007, exploring indications, infusion protocols and renal protective measures, infusion-related adverse reactions, nephrotoxicity, hypokalemia and outcomes."( [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Abusada A, N; Fica C, A; Gallardo A, C; Muñoz C, L; Novoa M, C; Quinteros A, R, 2010
)
0.36
" Adverse reactions were observed in 40% of treatments, predominating fever (25%)."( [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Abusada A, N; Fica C, A; Gallardo A, C; Muñoz C, L; Novoa M, C; Quinteros A, R, 2010
)
0.36
"infusion-related adverse reactions are frequent during amphotericin B deoxycholate therapy, but renal toxicity is occasionally observed."( [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Abusada A, N; Fica C, A; Gallardo A, C; Muñoz C, L; Novoa M, C; Quinteros A, R, 2010
)
0.36
" Hemolysis and acute toxicity investigations showed that BU-NLC was safe when given by intravenous injection with reduced toxicity."( The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
He, H; Li, F; Tang, X; Wang, L; Weng, Y; Yang, J, 2010
)
0.36
" However, administration of this drug is accompanied by substantial adverse effects."( Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Barker, DE; El-Sadr, W; Graybill, JR; Hamill, RJ; Javaly, K; Johnson, PC; Sobel, JD, 2010
)
0.36
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Clusters of adverse events following immunisation (AEFI) have been previously linked to other deoxycholate-split TIV formulations in Europe and Canada."( Adverse events associated with 2010 CSL and other inactivated influenza vaccines.
De Serres, G; Effler, PV; Kelly, HA; Skowronski, DM, 2011
)
0.37
" These results demonstrate that relatively higher concentrations of mixed micelles are toxic to Caco-2 cells, while phospholipids can attenuate the toxicity of the bile salts."( Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells.
Hu, F; Lu, Y; Qi, J; Tan, Y; Wu, W; Yin, Z, 2013
)
0.39
" Adverse events (AEs) and laboratory test results were monitored."( Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study.
Ascher, B; Havlickova, B; Hoffmann, K; Lippert, S; Walker, P; Wollina, U, 2014
)
0.64
" Pure AmB was found to hemolyse RBC and was very toxic to alveolar macrophage cells, as their viability rapidly declined from 93 to 56% when the AmB concentration increased from 1 to 8 μg/mL."( Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Adhikari, K; Gangadhar, KN; Srichana, T, 2014
)
0.4
"These observations indicate that naringenin was harmless upon exposure to rat gastrointestinal epithelium, clearly demonstrating the potential use of naturally occurring bioflavonoid as safe and novel pharmaceutical adjuvant in oral dosage forms as P-gp inhibitor."( Safety evaluation of naringenin upon experimental exposure on rat gastrointestinal epithelium for novel optimal drug delivery.
Nanjwade, BK; Patil, PA; Surampalli, G, 2016
)
0.43
" All subjects experienced at least 1 adverse event (AE)."( A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.
Fellmann, J; Lizzul, PF; Walker, P, 2015
)
0.65
" Overall, there were no unexpected toxicities in this preclinical study that might have precluded the safe administration of OH09208 to humans."( Preclinical safety evaluation of low molecular weight heparin-deoxycholate conjugates as an oral anticoagulant.
Byun, Y; Hwang, SR; Jeon, OC; Kim, JY; Moon, HT, 2016
)
0.43
" Anemia remained a concerning adverse effect."( Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015
)
0.42
" As expected, injection-site reactions such as pain, swelling, and bruising, which were mostly mild or moderate and transient, were common adverse events (AEs) reported in clinical trials."( Prevention and Management of Injection-Related Adverse Effects in Facial Aesthetics: Considerations for ATX-101 (Deoxycholic Acid Injection) Treatment.
Fagien, S; Jones, DH; McChesney, P; Subramanian, M, 2016
)
0.65
" However, some untoward adverse effects such as nephrotoxicity may limit its appropriate therapeutic use."( Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
Asadollahi, M; Hasibi, M; Jafari, S; Kouhi, A; Manshadi, SA; Salehi, M; Zarch, VV, 2017
)
0.46
" Few studies showing conflictive data about their efficacy and adverse events in pediatric population are available."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
" All patients reported adverse events (AE)."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
"N-methylglucamine antimoniate and amphotericin B deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
"Supramolecular encapsulation has been developed into a powerful tool in clearance of toxic substances and hazardous waste from living body and external environments."( Reversing the Cytotoxicity of Bile Acids by Supramolecular Encapsulation.
Chen, LX; Liu, Y; Liu, YH; Xu, X; Yu, Q; Zhang, YH; Zhang, YM, 2017
)
0.46
"Inhibition of bile salt export pump (BSEP) causes hepatic accumulation of toxic bile acid (BA), leading to hepatocyte death."( Identification of Bile Acids Responsible for Inhibiting the Bile Salt Export Pump, Leading to Bile Acid Accumulation and Cell Toxicity in Rat Hepatocytes.
Fukagai, M; Ito, K; Oizumi, K; Sekine, S; Susukida, T, 2017
)
0.46
" However, the emergence of severe adverse effects, such as nephrotoxicity, hepatotoxicity and hemolytic anemia, can limit its clinical use."( Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Altmeyer, C; Maissar Khalil, N; Mara Mainardes, R; Moraes Moreira Carraro, TC, 2017
)
0.46
"This post hoc analysis used pooled data from the REFINE trials to evaluate efficacy endpoints and adverse events following each treatment session to further characterize the ATX-101 treatment response and safety profile."( Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.
Beddingfield, FC; Beer, K; Carruthers, J; Dayan, SH; Donofrio, LM; Gross, TM; Humphrey, S; Jones, DH; Lizzul, PF; Schlessinger, J; Somogyi, C, 2018
)
0.48
" In both treatment groups, the incidence/severity of common injection-site adverse events declined over subsequent treatment sessions."( Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.
Beddingfield, FC; Beer, K; Carruthers, J; Dayan, SH; Donofrio, LM; Gross, TM; Humphrey, S; Jones, DH; Lizzul, PF; Schlessinger, J; Somogyi, C, 2018
)
0.48
"The development of an effective amphotericin B (AmB) topical formulation to replace the systemically toxic injections currently used in cutaneous leishmaniasis (CL) treatment is challenging due to poor absorption through the skin."( Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Pacienza-Lima, W; Ré, MI; Rossi-Bergmann, B; Sousa-Batista, AJ, 2019
)
0.51
" Eighty one patients subsequently answered questionnaires regarding improvement, satisfaction, and adverse effects."( Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Fabi, SG; Greene, R; Karavan, M; Zarbafian, M, 2020
)
0.56
" Adverse events were transient and limited to the treatment area."( Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Fabi, SG; Greene, R; Karavan, M; Zarbafian, M, 2020
)
0.56
" An expanded safe zone is described, allowing for individualized, comprehensive treatment of submental fat with ATX-101 according to each patient's anatomy and desired outcomes."( Novel Expanded Safe Zone for Reduction of Submental Fullness with ATX-101 Injection.
Chandawarkar, AA; Shridharani, SM, 2019
)
0.51
" The expanded safe zone was developed to isolate the distinct fat compartments of the submental area and includes a no-treatment zone to avoid the marginal mandibular nerve."( Novel Expanded Safe Zone for Reduction of Submental Fullness with ATX-101 Injection.
Chandawarkar, AA; Shridharani, SM, 2019
)
0.51
" The majority of adverse events consisted of temporary injection-site edema, numbness, and tenderness."( Novel Expanded Safe Zone for Reduction of Submental Fullness with ATX-101 Injection.
Chandawarkar, AA; Shridharani, SM, 2019
)
0.51
"An understanding of submental anatomy and careful assessment of each patient's submental fat allows for individualized treatment with ATX-101 beyond the central region of the neck without increased risk of adverse events."( Novel Expanded Safe Zone for Reduction of Submental Fullness with ATX-101 Injection.
Chandawarkar, AA; Shridharani, SM, 2019
)
0.51
" We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL."( Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.
Casas Vargas, MY; Ordoñez Rubiano, MF; Pérez Franco, JE; Rodríguez Galvis, MC, 2020
)
0.56
"Cryptococcosis is a life-threatening fungal infection, and its current treatment is toxic and subject to resistance."( N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
Carmo, PHF; Carvalho, VSD; Costa, MC; de Brito, CB; de Resende-Stoianoff, MA; de Souza, DG; Emídio, ECP; Ferreira, GF; Freitas, GJC; Holanda, RA; Magalhães, TFF; Paixão, TA; Ribeiro, NQ; Rocha, CEV; Santos, DA, 2020
)
0.56
" Despite DCA's widespread use, rare incidences of severe, systemic, long-term adverse events (AEs) have been reported."( Adverse Events of Injectable Deoxycholic Acid.
Choi, F; Juhasz, M; Lee, A; Mesinkovska, NA; Pham, CT; Sung, CT, 2020
)
0.85
" Deoxycholic acid injections in large volumes were more likely to cause severe adverse effects."( Adverse Events of Injectable Deoxycholic Acid.
Choi, F; Juhasz, M; Lee, A; Mesinkovska, NA; Pham, CT; Sung, CT, 2020
)
1.76
"Self-resolving, mild side effects and severe but rare adverse effects have been reported with DCA use making it a safe treatment for local adipose reduction."( Adverse Events of Injectable Deoxycholic Acid.
Choi, F; Juhasz, M; Lee, A; Mesinkovska, NA; Pham, CT; Sung, CT, 2020
)
0.85
"This study presents an update of properties and the use of DCA, as well as adverse events and possible complications."( Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications.
Cherubini, K; de Figueiredo, MAZ; Farina, GA; Salum, FG, 2020
)
2
"" Experimental studies developed in animals, clinical trials, literature reviews, case reports, and letters to the editor that included the DCA mechanism of action, dose, manner of use, adverse effects, and complications were selected."( Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications.
Cherubini, K; de Figueiredo, MAZ; Farina, GA; Salum, FG, 2020
)
2
"The most frequent adverse events are edema, local pain, bruise, and numbness, which usually spontaneously regress."( Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications.
Cherubini, K; de Figueiredo, MAZ; Farina, GA; Salum, FG, 2020
)
2
"Although DCA is beneficial for lysis of adipose tissue, clinicians should be aware about the adverse effects and risks involved with the use of this substance."( Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications.
Cherubini, K; de Figueiredo, MAZ; Farina, GA; Salum, FG, 2020
)
2
" Patient-reported satisfaction, psychological impact, and adverse events were monitored."( Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials.
Bhatia, AC; Bowen, B; Cohen, JL; Green, JB; Green, LJ; Humphrey, S, 2021
)
0.62
" No new treatment-related adverse events were reported."( Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials.
Bhatia, AC; Bowen, B; Cohen, JL; Green, JB; Green, LJ; Humphrey, S, 2021
)
0.62
" These results reveal an FXR-DCA-TNF-α axis that potentiates APAP hepatotoxicity, which could guide the clinical safe use of APAP."( FXR-Deoxycholic Acid-TNF-α Axis Modulates Acetaminophen-Induced Hepatotoxicity.
Gonzalez, FJ; Hao, H; Krausz, KW; Luo, Y; Takahashi, S; Wang, G; Wang, H; Yagai, T; Yan, N; Yan, T; Zhao, M, 2021
)
1.18
" We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported serious adverse events (SAEs)."( Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
Alves, F; Brack, M; Dahal, P; Guerin, PJ; Halleux, CM; Hawryszkiewycz, A; Maguire, BJ; Ngu, R; Olliaro, PL; Rashan, S; Singh-Phulgenda, S; Stepniewska, K, 2021
)
0.62
" The primary end point safety was evaluated by laboratory tests and the incidence of adverse events."( Safety and Efficacy of Deoxycholic Acid Injection for Hypogastric Fat Reduction: A Pilot Study.
Benito-Ruiz, J; Salvador, L, 2021
)
0.93
" The main local adverse events were edema (94."( Safety and Efficacy of Deoxycholic Acid Injection for Hypogastric Fat Reduction: A Pilot Study.
Benito-Ruiz, J; Salvador, L, 2021
)
0.93
"Deoxycholic acid may be a safe and effective option for reducing fat thickness in the hypogastric region, although given the cost/benefit ratio probably should be reserved for small deposits."( Safety and Efficacy of Deoxycholic Acid Injection for Hypogastric Fat Reduction: A Pilot Study.
Benito-Ruiz, J; Salvador, L, 2021
)
2.37
" Adverse events were monitored."( Safety and Efficacy of Deoxycholic Acid for Reduction of Upper Inner Thigh Fat.
Ortiz, A; Shafiq, F; Yuan, J, 2022
)
1.03
"There were no serious adverse events."( Safety and Efficacy of Deoxycholic Acid for Reduction of Upper Inner Thigh Fat.
Ortiz, A; Shafiq, F; Yuan, J, 2022
)
1.03
"Deoxycholic acid injection was safe and effective for reduction of upper inner thigh fat in this Phase I study."( Safety and Efficacy of Deoxycholic Acid for Reduction of Upper Inner Thigh Fat.
Ortiz, A; Shafiq, F; Yuan, J, 2022
)
2.47
" Due to the presence of important anatomical structures in the submental region, constant vigilance is required to report new adverse effects."( Adverse effects of deoxycholic acid in submandibular glands, submental, inguinal and subplantar regions: a study in rats.
Cherubini, K; Farina, GA; Koth, VS; Maito, FLDM; Payeras, MR; Salum, FG, 2022
)
1.05
" Safety was assessed by inquiries, subject diary entries of adverse events, laboratory tests, and vital sign checks."( A randomized, double-blind, multi-center, placebo-controlled, Phase 2 clinical trial to evaluate the efficacy and safety of DWJ211 in the treatment of moderate to severe submental fat.
Jung, CJ; Jung, JM; Kim, BJ; Lee, YW; Paik, SH; Shin, SH; Son, HS; Won, CH; Yang, HJ; Yoo, KH, 2022
)
0.72
" Local injection site reactions were the most common adverse events (AEs)."( Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction.
Ablon, G; Biesman, B; Cohen, J; Dayan, S; Downie, J; Fabi, S; Fagien, S; Gold, M; Gueta, R; Jones, D; Shamban, A; Shridharani, SM; Walker, P; Yoelin, S, 2023
)
0.91
" The low to moderate certainty of evidence found allows concluding that deoxycholic acid is effective in submental fat reduction, causing well-tolerated adverse effects."( Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction ‒ A systematic review and meta-analysis of randomized clinical trials.
Costa, MDMA; de Almeida, VL; Inocêncio, GSG; Meneses-Santos, D; Paranhos, LR; Rode, SM; Rodrigues, RPCB; Vieira, WA, 2023
)
1.39

Pharmacokinetics

The metabolism and enterohepatic circulation of deoxycholic acid (DCA), a major secondary bile acid in humans, was simulated using a linear multicompartmental physiologic pharmacokinetic model. This method was subsequently applied to pharmacokinetics studies of geniposide, baicalin, cholic acid and hyodeoxycholics acid in rats successfully.

ExcerptReferenceRelevance
" A dose-dependent increase in AUC and Cmax after the oral UDCA doses was observed in normal subjects."( A pharmacokinetic analysis of enterohepatic circulation of ursodeoxycholic acid, a drug with a high hepatic extraction but a small clearance.
Ishizaki, T; Kubota, K; Makino, I; Nakagawa, S; Shinozaki, K; Yamaguchi, A; Yamaoka, K, 1988
)
0.51
"The metabolism and enterohepatic circulation of deoxycholic acid (DCA), a major secondary bile acid in humans, was simulated using a linear multicompartmental physiologic pharmacokinetic model."( Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism.
Belforte, G; Bona, B; Cravetto, C; Hofmann, AF; Molino, G, 1987
)
0.76
"0 mg/kg), by comparison, achieved a lower Cmax (4."( Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
Amantea, MA; Bacher, J; Francis, PA; Lee, JW; Navarro, EE; Pizzo, PA; Walsh, TJ, 1994
)
0.29
"The pharmacokinetic profiles of a traditional formulation of amphotericin B (Fungizone) and novel nanosphere and mixed micelle delivery systems developed for amphotericin B were compared and described."( Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.
Barturen, C; Dios-Viéitez, MC; Echevarría, I; Renedo, MJ; Trocóniz, IF, 2000
)
0.31
"Model independent pharmacokinetic analysis of intravenous (iv) amphotericin B cochleates (CAMB), a new lipid-based drug delivery system, in mice (0."( Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
Movshin, DA; Segarra, I; Zarif, L, 2002
)
0.31
" The present study compares the pharmacokinetic characteristics of D-AmB with the alternative formulation of AmB in microemulsion (M-AmB), which has proved effective in a murine candidiasis model."( Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Ballesteros, MP; Brime, B; Bringas, P; Frutos, G; Frutos, P; Nieto, A, 2003
)
0.32
" In vitro and in vivo pharmacodynamic (PD) data, however, do not consistently support the concept of CI dosing based on the concentration-dependent activity of this agent and in vitro studies with AMB rarely account for the drug's high degree of protein binding."( In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Kontoyiannis, DP; Lewis, RE; Prince, RA; Wiederhold, NP, 2006
)
0.33
" A one-compartment in vitro pharmacodynamic model was used to simulate the steady-state PK parameters of bolus and CI AMB."( In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Kontoyiannis, DP; Lewis, RE; Prince, RA; Wiederhold, NP, 2006
)
0.33
" Pharmacokinetic parameter estimates were determined by a nonparametric population pharmacokinetic analysis of plasma drug concentrations following single intraperitoneal doses (0."( Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Chi, J; Kontoyiannis, DP; Lewis, RE; Prince, RA; Tam, VH; Wiederhold, NP, 2006
)
0.33
" Pharmacokinetic studies revealed that subsequent to administration of various formulations of amphotericin B, there was 32 mg/L amphotericin B in the systemic circulation of mice treated with tuftsin-bearing amphotericin B liposomes, while it was 25 mg/L for amphotericin B liposomes, 4 h post drug administration."( Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan, MA; Owais, M, 2006
)
0.33
" This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rats successfully."( Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.
Liang, Q; Liu, Q; Luo, G; Pan, Y; Pang, C; Ran, X; Wang, B, 2006
)
0.78
" Pharmacokinetic parameters in plasma were derived by model-independent techniques, and concentrations in ELF and PAM were calculated based on the urea dilution method and macrophage cell volume, respectively."( Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Alfaro, RM; Armstrong, D; Bacher, J; Groll, AH; Lyman, CA; Mickiene, D; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ, 2006
)
0.33
"The pharmacodynamic and pharmacokinetic (PK-PD) properties of amphotericin B (AmB) formulations against invasive pulmonary aspergillosis (IPA) are not well understood."( Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
Goodwin, J; Gregson, L; Hope, WW; Howard, SJ; Jensen, GM; Lestner, JM; Majithiya, J; Walsh, TJ, 2010
)
0.36
" The goals of this work were to develop and evaluate a physiologically based pharmacokinetic (PBPK) model to characterize the disposition properties of AmB administered as deoxycholate formulation in healthy rats and to examine the utility of the PBPK model for interspecies scaling of AmB pharmacokinetics."( Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.
Gershkovich, P; Kagan, L; Mager, DE; Wasan, KM, 2011
)
0.37
" Pharmacokinetic study revealed that DOMC-FA/PTX micelles exhibited higher AUC values and a prolonged residence time of drug in the blood circulation than that of Taxol injection."( Tissue distribution and pharmacokinetics evaluation of DOMC-FA micelles for intravenous delivery of PTX.
Guo, H; Guo, S; Hao, L; Li, C; Wang, F; Zhang, D; Zhang, Q; Zheng, D, 2013
)
0.39
" After subcutaneous administration, the pharmacokinetic study showed that IVM-SPC-SDC-MMs and commercially available IVM injection were bioequivalent."( Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study.
Dong, J; Fu, Y; Gong, T; Lian, X; Song, X, 2016
)
0.43
"This phase 1 study evaluated the safety, pharmacokinetics (PK), and pharmacodynamic effects of ATX-101 (100-mg total dose)."( A phase 1 pharmacokinetic study of ATX-101: serum lipids and adipokines following synthetic deoxycholic acid injections.
Lee, D; Walker, P, 2015
)
0.64
" Its long terminal half-life and retention in tissues suggest that single or intermittent dosing regimens are feasible, and these should be actively investigated in both preclinical models and in clinical trials."( Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
Bicanic, T; Hope, W; Salim, R; Stone, NR, 2016
)
0.43
" Furthermore, the mechanism of action of the best compound was assessed, and in silico studies to evaluate the physicochemical and pharmacokinetic properties were also conducted."( Novel steroid derivatives: synthesis, antileishmanial activity, mechanism of action, and in silico physicochemical and pharmacokinetics studies.
Calixto, SL; Coimbra, ES; da Silva Martins, J; da Silva, AD; da Trindade Granato, J; Dos Santos, JA; Prado da Silva, N, 2018
)
0.48
" In this study, the pharmacokinetic parameters of both CBBP and NBBP were measured in rats with a new surrogate analyte LC-MS method using stable isotopes as surrogate analytes (D4-TUDCA, D4-TCDCA, D4-UDCA and D4-CDCA) with response factors validated in authentic matrix (plasma) for simultaneously monitoring the authentic analytes (TUDCA, TCDCA, UDCA and CDCA)."( A validated surrogate analyte UPLC-MS/MS assay for quantitation of TUDCA, TCDCA, UDCA and CDCA in rat plasma: Application in a pharmacokinetic study of cultured bear bile powder.
Li, Y; Liu, S; Liu, X; Ma, Y; Shi, R; Sun, X; Wang, T; Yang, L; Zan, B; Zhao, Y, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the nasal absorption enhancement of insulin by sodium deoxycholate (SDC) in combination with cyclodextrins (CD)."( Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins.
Jiang, XG; Yao, J; Zhang, Y, 2001
)
0.31
" The effect of SDC in combination with CD on the leucine aminopeptidase (LAP) activity in the nasal mucosa was observed."( Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins.
Jiang, XG; Yao, J; Zhang, Y, 2001
)
0.31
"The therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate was evaluated in treatment of murine coccidioidomycosis."( Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.
González, G; González, GM; Graybill, JR; Najvar, LK, 2007
)
0.34
"This study indicates that caspofungin has efficacy against systemic coccidioidomycosis in a murine model given in combination with amphotericin B deoxycholate."( Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.
González, G; González, GM; Graybill, JR; Najvar, LK, 2007
)
0.34
" Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, is closely related to Mycograb, which showed a survival advantage in combination with AMB in a phase III human trial."( Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Conde, H; Drusano, GL; Fregeau, C; Liu, W; Louie, A; Stein, DS; Vanscoy, BD; Zack, JZ, 2011
)
0.37
"This study was aimed to investigate the effect of all-trans retinoic acid (ATRA) combined with SBA-Na on the biologic activities of human leukemia K562 and Kasumi-1 cell lines and their mechanism."( [Inhibitory effect of all-trans retinoic acid combined with SBA-Na on K562 and Kasumi-1 cell lines in vitro].
Chang, C; Fan, H; Guo, B; Li, SX; Lin, J; Liu, Y; Lu, XC; Ran, HH; Yang, B; Yang, Y; Zhai, B; Zhang, L; Zhu, HL, 2013
)
0.39
" The relevant transport systems were then investigated in terms of the drug-drug interactions of AmB-DOC with antivirals that might potentially be used concomitantly."( Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.
Kočíncová, J; Mandíková, J; Trejtnar, F; Volková, M, 2014
)
0.4
" Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids."( [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS, 2014
)
0.7
"Functional xenogeneic heart valve substitutes with a low immunologic load can be produced by decellularization combined with enzymatic removal of DNA and partial deglycosylation of dpPHV."( Decellularization combined with enzymatic removal of N-linked glycans and residual DNA reduces inflammatory response and improves performance of porcine xenogeneic pulmonary heart valves in an ovine in vivo model.
Cebotari, S; Ciubotaru, A; Findeisen, K; Goecke, T; Haverich, A; Hilfiker, A; Hoeffler, K; Ramm, R; Sarikouch, S; Theodoridis, K; Tudorache, I, 2020
)
0.56
"The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain."( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid.
Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021
)
0.83
" Laboratory adverse events (grade 3 or 4), such as severe anemia, were less frequent with VCZ + 5FC use than with AmB-D combined with 5FC or Flu use."( Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022
)
0.72
"Our results suggest that AmB-D combined with 5FC remains the more efficacious induction regimen compared to AmB-D plus Flu, and that VCZ + 5FC might be a potential alternative when the standard regimen is not readily available, accessible, tolerated, or effective."( Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022
)
0.72

Bioavailability

Ursodeoxycholic acid (UDCA) is a cholesterolic gallstone dissolving agent. It is well absorbed from intestine, undergoes little biotransformation during hepatic passage, and is 7-dehydroxylated by colonic bacteria.

ExcerptReferenceRelevance
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
" At concentrations below 5 mM, the rate of absorption of bile acids was directly proportional to concentration, so that "clearance" could be calculated."( Colonic absorption of unconjugated bile acids: perfusion studies in man.
Hofmann, AF; Mekhjian, HS; Phillips, SF, 1979
)
0.26
" Ursodeoxycholic acid is well absorbed from intestine, undergoes little biotransformation during hepatic passage, and is 7-dehydroxylated by colonic bacteria."( Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid.
Makino, I; Nakagawa, S, 1978
)
0.99
" The 600-mg dose caused a decrease in drug bioavailability as measured by the total amount excreted in 24 hr."( Effect of surfactants on absorption through membranes V: Concentration-dependent effect of a bile salt (sodium deoxycholate) on absorption of a poorly absorbable drug, phenolsulfonphthalein, in humans.
Gouda, MW; Khalafalah, N; Khalil, SA, 1977
)
0.26
" Large dose did not retard the absorption rate and showed a significant choleretic effect for a few hours."( Metabolism of 3,7-dioxo-5 beta-cholanoic acid in the biliary fistula rodents and rabbits.
Asanuma, Y; Hoshita, T; Miki, S; Une, M, 1990
)
0.28
"A model has been developed that permits calculation of the absorption rates of newly formed and deconjugated deoxycholic acid (DCA) from the intestine, the fractional absorption rate of deconjugated DCA and the daily rate of formation of DCA."( A new model to assess deoxycholic acid metabolism in health using stable isotope dilution technique.
Paumgartner, G; Stellaard, F, 1987
)
0.8
" Nor-ursodeoxycholate was well absorbed from the intestine and secreted in the bile as a glucuronide as well as the unchanged compound, but conjugation with glycine and taurine was not observed."( Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit.
Cohen, BI; Hagey, LR; Hofmann, AF; Mosbach, EH; Rothschild, MA; Stenger, RJ; Yoon, YB, 1986
)
0.53
"The bioavailability of ursodeoxycholic acid (UDCA), a cholesterolic gallstone dissolving agent, has been analysed in seven healthy human volunteers."( Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man.
Berthaux, N; Infante, R; Metman, EH; Parquet, M; Raizman, A; Rambaud, JC, 1985
)
0.79
" Hyodeoxycholic acid was well absorbed by the human intestine."( Intestinal absorption, excretion, and biotransformation of hyodeoxycholic acid in man.
Huguet, C; Infante, R; Jarrige, P; Parquet, M; Raizman, A; Riottot, M; Sacquet, E, 1983
)
1.06
" A method has been derived from pharmacokinetic principles used for the calculation of bioavailability of drugs according to the route of administration (i."( Noninvasive measurement of nutrient portal blood shunting: an experimental study with [14C]ursodeoxycholic acid.
Blondiau, P; Boschat, M; Groussard, M; Huguet, C; Infante, R; Moreels, R; Nordlinger, B; Parquet, M,
)
0.35
" The absorption rate was small, especially in the colon (0."( Appearance of 14C-polyethylene glycol 4000 in intestinal venous blood: influence of osmolarity and laxatives, effect on net water flux determination.
Görig, H; Winne, D, 1982
)
0.26
" Since UDCA acts partly by reducing the intestinal absorption of hydrophobic endogenous bile salts and is poorly absorbed from the intestine, a multiple dose regimen has been advocated."( Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
Salemans, JM; Tangerman, A; Van Berge-Henegouwen, GP; van Buuren, HR; van de Meeberg, PC; van Erpecum, KJ; van Hattum, J; Wolfhagen, FH, 1996
)
0.59
" Papp of IDM was greater than that of TAT, indicating that the order corresponded with that of in vivo bioavailability after oral administration of their PEG 600 solutions."( Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives.
Hayashi, M; Sudo, R; Takahashi, M; Watanabe, E, 2000
)
0.31
"The pharmacokinetics and bioavailability of triamcinolone acetonide were determined to investigate buccal absorption from the mucoadhesive gels in rabbits."( Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits.
Bum, JP; Choi, JS; Shin, SC, 2000
)
0.31
" reuteri on the bioavailability of isoflavones present in soygerm powder was examined."( Combined use of Lactobacillus reuteri and soygerm powder as food supplement.
De Boever, P; Verstraete, W; Wouters, R, 2001
)
0.31
" Initial absorption rate constants were determined by the plot of log% remaining amount of drug in perfusate vs time."( The influence of absorption enhancers on nasal absorption of acyclovir.
Chavanpatil, MD; Vavia, PR, 2004
)
0.32
" LMWH-DOCA was completely dissolved in 10% DMSO solution, and its bioavailability in the oral dose was significantly increased (17."( Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Byun, Y; Kim, SK; Kumar, TS; Lee, E; Lee, S; Lee, YK; Moon, HT; Vaishali, B, 2006
)
0.58
"We validated the application of the surface plasmon resonance (SPR) technique to reliably determine adhesion of drugs to the intestinal wall using heparin-DOCA conjugates, developed to enhance the oral absorption of poorly absorbed heparin."( Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance.
Byun, Y; Choi, K; Kim, CY; Kim, K; Kim, SK; Kwon, IC; Lee, S; Park, JH; Park, K, 2005
)
0.33
" When the ceftriaxone/DCEA formulation was administered into a nonclosed segment of duodenum of rats, C(max) (the maximum drug concentration in plasma) and AUC (area under the curve) were significantly increased and its bioavailability was increased up to 70%."( Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone.
Byun, Y; Chae, SY; Kim, SK; Kumar, TS; Lee, DY; Lee, S; Park, K, 2005
)
0.33
" These additives increased intestinal permeability (P(app)) and absorption rate constant (K(a)) up to two and fourfold, respectively."( In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Chawla, HP; Panchagnula, R; Sharma, P; Varma, MV,
)
0.13
"05) in extent of bioavailability between the liquid suppository and oral suspension as indicated by the values of AUC(0 - infinity), 17."( Thermally reversible in situ gelling carbamazepine liquid suppository.
El-Kamel, A; El-Khatib, M,
)
0.13
"3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), the 7alpha-fluorine analog of hyodeoxycholic acid (HDCA), was synthesized to improve bioavailability and stability of ursodeoxycholic acid (UDCA)."( 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Asciutti, S; Baldoni, M; Camaioni, E; Castellani, D; Clementi, M; Clerici, C; Fiorucci, S; Giuliano, V; Mazzocchi, A; Morelli, A; Morelli, O; Nardi, E; O'Connell, NC; Orlandi, S; Pellicciari, R; Renga, B; Sabatino, G; Sadeghpour, B; Setchell, KD, 2006
)
0.55
" The use of 8 mmol x L(-1)/dose sodium taurocholate and 10 mmol x L(-1)/dose sodium deoxycholate could be able to potentially improve the bioavailability of insulin by pulmonary route."( Deposition of insulin powders for inhalation in vitro and pharmacodynamic evaluation of absorption promoters in rats.
Yang, DB; Zhang, XS; Zhu, H; Zhu, JB, 2005
)
0.33
"The purpose of this study was to investigate the transport characteristics and mechanisms for discovering the possible causes of the low bioavailability of astragaloside IV and to develop an absorption enhancement strategy."( Absorption enhancement study of astragaloside IV based on its transport mechanism in caco-2 cells.
Huang, CR; Li, H; Lv, H; Sun, JG; Wang, GJ; Wu, XL; Xie, HT,
)
0.13
" The data obtained showed that MCP was well absorbed nasally where almost 90% of the drug was absorbed after 60min from the rat nasal cavity."( Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats.
Abd ElHady, SS; Awad, GA; Mortada, ND; Zaki, NM, 2006
)
0.33
" LHD was pre-formulated with dimethyl sulfoxide (DMSO) as solubilizer to further improve its oral bioavailability (9."( Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Byun, Y; Kim, CY; Kim, SK; Lee, DY; Lee, E; Lee, YK; Moon, HT, 2007
)
0.66
"The aim of this investigation was to develop novel oil-in-water (o/w) nanoemulsions containing Saquinavir (SQV), an anti-HIV protease inhibitor, for enhanced oral bioavailability and brain disposition."( Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Amiji, MM; Shahiwala, A; Vyas, TK, 2008
)
0.35
" We hypothesized that bile salts could be used to improve the bioavailability of poly(lactide-co-glycolide) (PLGA) nanoparticles by protecting them during their transport through the gastrointestinal tract and enhancing their absorption by the intestinal epithelia."( The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles.
Balderrama, F; Fahmy, TM; Look, M; Perica, K; Samstein, RM, 2008
)
0.74
" BI (oral I) containing SBE had greater reduction of blood glucose than BII (oral II) ,showing that SBE increased the bioavailability of insulin."( Evaluation of the pharmacodynamic activity of insulin from bilosomal formulation.
Attama, AA; Ayogu, IJ; Ayolugbe, CI; Ogbonna, O, 2009
)
0.35
"5 showed optimum oral efficacy and its bioavailability was about 24% in rats."( Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Al-Hilal, TA; Byun, Y; Jeon, OC; Kim, CY; Kim, SK; Moon, HT; Park, JW, 2010
)
0.36
" Bioavailability of insulin from selected formulations was compared with an intranasal solution and subcutaneous injection in rabbits."( Enhancement of the intranasal delivery of insulin via a novel mucoadhesive Carbopol gel.
El-Dakrouri, WA; Ghorab, MK; Ghorab, MM; Ibrahim, HK, 2010
)
0.36
" After orally administration of PTX-loaded DHC micelles, the bioavailability was threefold compared with that of an orally dosed Taxol®."( Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system.
Dai, Y; Deng, Y; Huo, M; Li, H; Masoud, J; Shi, X; Zhou, J, 2010
)
0.62
"This study was designed to develop a solid oral dosage form of deoxycholic acid (DOCA)-conjugated low-molecular-weight heparin (LMWH) and to evaluate its oral absorption, distribution, and metabolic stability for the prospect of providing an orally bioavailable LMWH."( Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Al-Hilal, TA; Byun, Y; Jeon, OC; Kim, CY; Kim, SK; Lim, KM; Moon, HT; Park, JW, 2011
)
0.83
"The main purpose of this study was to evaluate liposomes containing a bile salt, sodium deoxycholate (SDC), as oral drug delivery systems to enhance the oral bioavailability of the poorly water-soluble and poorly permeable drug, cyclosporine A (CyA)."( Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.
Guan, P; Hu, F; Lian, R; Lu, Y; Niu, M; Qi, J; Wu, W, 2011
)
0.37
" Ins-SD-Comp-loaded PLGA nanoparticles have the potential to reduce serum glucose levels and increase the oral bioavailability of insulin."( Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin.
Cui, F; Kawashima, Y; Liang, N; Sun, S; Xia, D, 2011
)
0.37
" However, due to its impermeability across the gastrointestinal mucosa, oral bioavailability of the drug was relatively low."( Improvement of oral bioavailability of glycyrrhizin by sodium deoxycholate/phospholipid-mixed nanomicelles.
Fu, S; Han, J; Jin, S; Lu, Y; Lv, Q; Qi, J; Wu, W; Yuan, H, 2012
)
0.38
" After administration of mangiferin at a dose of 30 mg/kg combining with sodium deoxycholate, the bioavailability of mangiferin increased four-fold, and this may be due to sodium deoxycholate weakening the compactness between lecithin molecules and increased the paracellular permeability."( Increased absorption of mangiferin in the gastrointestinal tract and its mechanism of action by absorption enhancers in rats.
Gu, Y; Meng, L; Ren, T; Tang, X; Tian, B; Wang, X; Zhang, Y, 2013
)
0.39
"The aim of the investigation was to compare the effectiveness of two absorption enhancers, sodium caprate (C10) and sodium deoxycholate (SDC), in increasing the bioavailability of a poorly absorbed paracellar flux drug, berberine chloride, across the intestinal mucosae of rats in vivo, together with examination of their effects on mucosal damage."( Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats.
Dong, W; Fan, D; Li, J; Sun, W; Tang, X; Wu, X, 2013
)
0.39
" Among all the compounds, 6ODS-LHbD showed the highest oral bioavailability in rats (19."( Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
Al-Hilal, TA; Byun, Y; Chang, YT; Hwang, SR; Jeon, OC; Kang, JH; Kang, YM; Kim, HS; Kim, SH; Seo, DH; Yang, VC, 2012
)
0.62
"Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections."( Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP, 2013
)
0.39
"5 showed 284% and 145% bioavailability relative to Lipanthyl® and solid dispersion pellets (FB:PEG = 1:3), respectively."( Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating.
Dong, F; Hu, F; Li, S; Lu, Y; Qi, J; Wu, W; Xie, Y, 2013
)
0.39
" Its oral bioavailability is low and its intestinal absorption mechanism is not clear."( Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers.
Li, X; Lu, Y; Yin, Z; Yu, Y; Zhao, X, 2013
)
0.39
" However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects."( Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
Byun, Y; Park, JW, 2014
)
0.65
" Orally administered LHe-tetraD showed remarkable systemic anticoagulation activity and high oral bioavailability of 33."( Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
Al-Hilal, TA; Alam, F; Byun, Y; Chung, SW; Kim, IS; Kim, K; Kim, SY; Kwon, IC; Park, J; Park, JW, 2014
)
0.4
" However, the anticoagulant activity and poor oral bioavailability of heparin limit its use as an anti-inflammatory agent."( Intracellular delivery of desulfated heparin with bile acid conjugation alleviates T cell-mediated inflammatory arthritis via inhibition of RhoA-dependent transcellular diapedesis.
Alam, MM; Byun, YR; Hwang, SR; Jang, JA; Kang, JH; Kang, YM; Kim, IS; Kim, SY; Sa, KH; Sung, S, 2014
)
0.4
"5 times higher than that of MTC injection, and these micelles can enhance the bioavailability of MTC."( Deoxycholic acid-grafted PEGylated chitosan micelles for the delivery of mitomycin C.
Guan, J; Jin, Y; Shi, NQ; Zhang, XR; Zhao, Y; Zhu, HY, 2015
)
1.86
" The resulting LHTD4/DCK complex showed significantly enhanced oral bioavailability (34."( Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Al-Hilal, TA; Alam, F; Byun, Y; Chung, SW; Kim, HS; Kim, SY; Mahmud, F; Seo, D, 2014
)
0.61
" However, the use of AmB through oral administration is restricted due to its low solubility and stability in aqueous solution, which is the cause for its poor bioavailability and highly varying absorption."( Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Adhikari, K; Gangadhar, KN; Srichana, T, 2014
)
0.4
"This work aims to develop novel benznidazole (BZN) solid dispersions (SD) to improve its solubility and bioavailability properties."( Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.
Arán, VJ; Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Palmeiro-Roldán, R; Torrado-Durán, S; Torrado-Santiago, S, 2014
)
0.4
" In general, this research provides important information about the factors influencing the bioaccessibility of emulsified vitamin E, which could be used to design more effective emulsion-based delivery systems for increasing the oral bioavailability of this important bioactive component."( Enhancing vitamin E bioaccessibility: factors impacting solubilization and hydrolysis of α-tocopherol acetate encapsulated in emulsion-based delivery systems.
Decker, EA; McClements, DJ; Xiao, H; Yang, Y, 2015
)
0.42
" However, its low bioavailability limits its clinical efficacy for the treatment of osteoporosis."( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate.
Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015
)
0.42
"In this paper, suet oil (SO) was used to improve the oral bioavailability of CIT and enhance its antiosteoporosis effect and absorption."( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate.
Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015
)
0.42
"The increased antiosteoporosis effects and bioavailability of CIT-SO-DOC self-assembled nanomicelles were due to an increase in absorption of CIT by reducing the particle sizes of CIT."( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate.
Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015
)
0.42
" Sodium citrate, SDS and deoxysodium cholate serve as excellent absorption enhancers which are useful for the related research improving the oral bioavailability of OMT."( Absorption mechanism of oxymatrine in cultured Madin-Darby canine kidney cell monolayers.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" Finally, bioavailability in rats and tumor growth inhibition in the squamous cell carcinoma (SCC7) model after oral administration of the OXA/DCK nanocomplex were investigated compared to pure OXA."( Preparation of Oxaliplatin-Deoxycholic Acid Derivative Nanocomplexes and In Vivo Evaluation of Their Oral Absorption and Tumor Growth Suppression.
Byun, Y; Jeon, OC; Park, JW, 2016
)
0.73
" We also assessed its permeability across a Caco-2 cell monolayer and the bioavailability of the intrajejunally administered PTH/LysDOCA complex compared with PTH (1-34) in rats."( Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.
Byun, Y; Hwang, SR; Park, JW; Seo, DH,
)
0.34
" Finally, drug bioavailability of the BH."( Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation.
Aboud, HM; Ali, AA; El-Nabarawi, MA; Godah, AH; Hassan, AH, 2016
)
0.43
"2HCl-optimized buccal mucoadhesive formulation showed percentage relative bioavailability of 177%."( Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation.
Aboud, HM; Ali, AA; El-Nabarawi, MA; Godah, AH; Hassan, AH, 2016
)
0.43
" The oral bioavailability of carboplatin/DOCA complex and native carboplatin were calculated as 24."( Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
Alam, F; Byun, Y; Choi, JU; Chung, SW; Kim, IS; Kim, SW; Kim, SY; Lee, DS; Mahmud, F, 2017
)
0.46
" The oral bioavailability and pharmacokinetics of cefotaxime was assessed in rats (n = 6 per group) after single dose of drug-encapsulated in liposomes containing bile salt, drug in conventional liposomes, and cefotaxime solution (oral and intravenous)."( Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug.
Arafat, M; Kirchhoefer, C; Löbenberg, R; Mikov, M; Sarfraz, M, 2017
)
0.46
" The total oral bioavailability of cefotaxime in liposomes containing bile salt was found to be 5-times higher compared to cefotaxime solution and twice as much as in conventional liposomes."( Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug.
Arafat, M; Kirchhoefer, C; Löbenberg, R; Mikov, M; Sarfraz, M, 2017
)
0.46
" The nano-sized liposomes containing sodium deoxycholate were able to reduce the leakage of encapsulated cefotaxime in the gut due to the improved vesicle stability and to enhance the oral bioavailability of acid-labile drugs up to 5-fold."( Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug.
Arafat, M; Kirchhoefer, C; Löbenberg, R; Mikov, M; Sarfraz, M, 2017
)
0.46
"5 fold enhancement in bioavailability as compared with drug solution."( Design, Optimization and Characterization of Granisetron HCl Loaded Nano-gel for Transdermal Delivery.
Aggarwal, G; Chaudhary, H; Kumar, V, 2017
)
0.46
" Further pharmacokinetic studies disclose an oral bioavailability of 15."( Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery.
Fan, W; Gan, Y; Guo, S; He, S; Hovgaard, L; Li, X; Xia, D; Yang, M; Zhu, C; Zhu, Q, 2018
)
0.48
"Currently, the most prominent barrier to the success of orally delivered paclitaxel (PTX) is the extremely limited bioavailability of delivered therapeutic."( N-Deoxycholic acid-N,O-hydroxyethyl Chitosan with a Sulfhydryl Modification To Enhance the Oral Absorptive Efficiency of Paclitaxel.
Cai, H; Chen, Q; Fu, Y; Huo, M; Mu, Y; Xu, W; Yao, L; Yin, T; Yu, Y; Zhou, J, 2017
)
1.18
" Furthermore, the TMNM had greater bioavailability (215%) than the Tol solution."( Toltrazuril mixed nanomicelle delivery system based on sodium deoxycholate-Brij C20 polyethylene ether-triton x100: Characterization, solubility, and bioavailability study.
Fan, G; Fu, H; Liu, C; Peng, G; Ren, D; Shi, F; Shu, G; Yin, L; Yuan, Z; Zhang, L; Zhao, L; Zhou, J, 2018
)
0.48
"Liposomes are promising systems for the delivery of macromolecules and poorly absorbed drugs, owing to their ability to compartmentalize drugs, their biodegradability and biocompatibility."( Enhancing the Intestinal Permeation of the Chondroprotective Nutraceuticals Glucosamine Sulphate and Chondroitin Sulphate Using Conventional and Modified Liposomes.
Abdel-Hamid, S; Agiba, AM; Eldin, AB; Geneidi, AS; Nasr, M, 2018
)
0.48
" In light of the above, liposomes can be considered promising oral permeation-enhancer system for GluS and CS, which is worthy of future bioavailability experimentation."( Enhancing the Intestinal Permeation of the Chondroprotective Nutraceuticals Glucosamine Sulphate and Chondroitin Sulphate Using Conventional and Modified Liposomes.
Abdel-Hamid, S; Agiba, AM; Eldin, AB; Geneidi, AS; Nasr, M, 2018
)
0.48
"Proteins and peptides are poorly absorbed via oral administration because of the gastrointestinal tract environment and lysosomal digestion after apical endocytosis."( A Delivery System for Oral Administration of Proteins/Peptides Through Bile Acid Transport Channels.
Bin, W; Li, X; Liao, S; Sun, C; Tu, B; Wang, W; Wu, S, 2019
)
0.51
"Docetaxel (DTX) was effective in the treatment of neoplasm but could only be administered intravenously with the poor oral bioavailability owing to its undesirable solubility, remarkably metabolic conversion, and other factors."( Preparation of Deoxycholate-Modified Docetaxel-Cimetidine Complex Chitosan Nanoparticles to Improve Oral Bioavailability.
Fang, T; Shen, Q; Sun, L; Xu, Y; Yang, Y, 2019
)
0.51
" Even though 60% of an oral dose is quickly absorbed via the gastrointestinal tract, the absolute bioavailability of RH is only 2-3% in humans due to extensive first-pass metabolism."( Spray-dried raloxifene submicron particles for pulmonary delivery: Development and in vivo pharmacokinetic evaluation in rats.
Beck, RCR; de Araujo, BV; Dos Santos, J; Fontana, MC; Forgearini, B; Guterres, SS; Laureano, JV; Pohlmann, AR, 2020
)
0.56
" However, CBD is lipophilic and highly photooxidative with low oral bioavailability in plasma and brain."( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid.
Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021
)
0.83
"The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain."( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid.
Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021
)
0.83
" This resulted in a 282% improvement in oral bioavailability in rats."( Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity.
Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Maharjan, R; Pangeni, R; Park, JW; Subedi, L, 2021
)
0.62
" However, the poor oral bioavailability of EMO and the insufficient monotherapy therapy compromise its efficacy."( Deoxycholic acid-chitosan coated liposomes combined with in situ colonic gel enhances renal fibrosis therapy of emodin.
Fan, X; Hou, Y; Piao, JG; Sun, J; Wei, Y; Xu, Z; Yao, W; Zhang, K; Zhang, Q; Zhu, L, 2022
)
2.16
"Overall, the combination of DCS-Lips and EMO-IGE alleviated renal fibrosis effectively, resulting from the improved oral bioavailability of EMO by DCS-Lips and the restoration of gut microbiota by EMO-IGE, thus, presenting an innovative and promising potential for renal fibrosis treatment."( Deoxycholic acid-chitosan coated liposomes combined with in situ colonic gel enhances renal fibrosis therapy of emodin.
Fan, X; Hou, Y; Piao, JG; Sun, J; Wei, Y; Xu, Z; Yao, W; Zhang, K; Zhang, Q; Zhu, L, 2022
)
2.16
"0-fold greater oral bioavailability compared with free TRP."( Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis.
Byun, Y; Chang, KY; Cho, SS; Kang, SH; Kim, KT; Pandey, P; Park, JW; Shim, JH; Subedi, L, 2022
)
0.72
" The drug has poor oral bioavailability and undergoes a significant first-pass metabolism."( Incorporating sodium deoxycholate endorsed the buccal administration of avanafil to heighten the bioavailability and duration of action.
Abd-Allah, FI; Ahmed, TA; Al-Hejaili, OD; Alhakamy, NA; El-Sawy, HS; El-Say, KM; Safo, MK, 2023
)
0.91

Dosage Studied

The study was designed to develop a solid oral dosage form of deoxycholic acid (DOCA)-conjugated low-molecular-weight heparin (LMWH)

ExcerptRelevanceReference
" Oral dosage with deoxycholate (1."( Some effects of deoxycholate administration on the metabolism of cholesterol in man.
Gallo-Torres, HE; Hamilton, JG; Miller, ON, 1979
)
0.26
" By means of electronmicroscopy we detected in the CDCA-group already with 20 mg/kg/day microstructural alterations of the liver that increased with elevation of the dosage and duration of treatment."( [The influence of chenodeoxycholic acid and ursodeoxycholic acid on the hepatic structure of the rat (author's transl)].
Korte, L; Leuschner, U; Schneider, M, 1979
)
0.57
"Twenty-three patients with gallstones were treated with two dosage levels of ursodeoxycholic acid, 600 mg/day and 150 mg/day."( Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid.
Makino, I; Nakagawa, S, 1978
)
0.7
" Dose-response inhibition of water transport in everted hamster jejunal segments was obtained with two long chain detergents (sodium dodecyl sulfate and dioctyl sodium sulfocuccinate), a fatty acid (ricinoleate), and dihydroxy bile salts (deoxycholate, chenodeoxycholate, and taurodeoxycholate), whereas no activity was seen with trihydroxy (cholate, glycocholate, and taurocholate) and tri-keto (dehydrocholate) bile salts."( Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity.
Bass, P; Benz, L; Cline, WS; Gullikson, GW; Lorenzsonn, V; Olsen, WA, 1977
)
0.26
" A linear dose-response relationship was observed for hGH in starved fish and the level of absorption in fed fish was influenced by the time interval from the last meal."( Absorption of bioactive human growth hormone after oral administration in the common carp (Cyprinus carpio) and its enhancement by deoxycholate.
Gertler, A; Hertz, Y; Madar, Z; Tchelet, A, 1991
)
0.28
" Only bile, but not secretin intravenously, both applied in a dosage equivalent with respect to their hydrokinetic action, caused a significant increase of enzyme output and enzyme concentration as well."( Na-taurodeoxycholate acts as a specific intestinal stimulus of exocrine pancreatic secretion in man.
Danzl, C; Fiedler, F; Hempen, I; Hotz, E; Lehnert, P; Mitra, H; Riepl, R, 1987
)
0.27
" To investigate the dose-response relationship to ursodiol administration, we planned a few studies in patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and chronic hepatitis (CH)."( Effect of different doses of ursodeoxycholic acid in chronic liver disease.
Battezzati, PM; Bertolini, E; Crosignani, A; Ghezzi, C; Petroni, ML; Podda, M; Zuin, M, 1989
)
0.56
" Hyodeoxycholic acid and hyodeoxy-oxazoline [2-(3 alpha,6 alpha-dihydroxy-24-nor-5 beta-cholanyl)-4,4-dimethyl-2- oxazoline] at the same dosage effectively prevented gallstones, while the trihydroxy bile acid, hyocholic acid, was not effective."( Role of hydrophilic bile acids and of sterols on cholelithiasis in the hamster.
Cohen, BI; Finver-Sadowsky, J; McSherry, CK; Mosbach, EH; Singhal, AK, 1984
)
0.83
" Activities of AST in treated guinea pigs were significantly higher than those in controls for only 2 dosage levels (0."( Serum concentration of bile acids in guinea pigs as an indicator of liver damage caused by aflatoxins.
Baetz, AL; McLoughlin, ME, 1983
)
0.27
"In a prospective dosage response study of 84 patients with radiolucent gall bladder stones treated with ursodeoxycholic acid (UDCA), a dose of 500 mg daily was as effective as 1,000 mg daily."( Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones.
Bateson, MC; Bouchier, IA; Neligan, P; Ross, PE; Trash, DB, 1983
)
1.04
" Fifteen gallstone patients were treated with ursodeoxycholic acid at a daily dosage of 15 mg per kg body weight for about 4 weeks before cholecystectomy."( Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Angelin, B; Einarsson, K; Ewerth, S, 1983
)
1.08
"A double-blind clinical trial comparing ursodesoxycholic acid and chenodesoxycholic acid in patients with cholesterol stones in the gall-bladder showed that ursodesoxycholic acid was superior to the older drug not so much in percentage of biliary calculi dissolved but in dosage reduction (50%) and improved clinical and biological tolerance."( [Treatment of cholesterol gallstones with ursodesoxycholic acid (author's transl)].
Bernades, P; Bertrand, L; Bouvry, M; Colin, R; Geffroy, Y; Hecht, Y; Klepping, C; Lambert, R; Levy, VG; Michel, H; Paliard, P; Paris, J; Quinton, A, 1982
)
0.26
"A dose-response study comparing ursodeoxycholic and chenodeoxycholic acid was carried out in six men with asymptomatic radiolucent gallstones present in well-visualizing gallbladders."( Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study.
Carlson, GL; Hofmann, AF; Larusso, NF; Ott, BJ; Thistle, JL; Turcotte, J, 1982
)
0.77
"In spite of many reports which suggested the efficacy of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) on cholesterol gallstone dissolution, problems still remain to be solved, such as the ideal dosage and duration of treatment to obtain maximal benefit with minimal untoward effects."( Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
Iwamura, K, 1982
)
0.71
" The use and dosage of conventional amphotericin B (deoxycholate-suspended formulation) is limited by its toxicity, especially nephrotoxicity."( [Remission of invasive sinusal and pulmonary aspergillosis with liposomal amphotericin B in a patient with chronic lymphatic leukemia following failure with conventional amphotericin].
Acebedo, G; Jodar, JM; López, A; Palacio, C, 1994
)
0.29
" Clinical trials in humans must examine carefully the therapeutic-toxic ratio in dose-escalation protocols to determine the optimal dosage strategy for this agent."( Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis.
Perfect, JR; Wright, KA, 1994
)
0.29
" Dosage for both drugs was 10 mg/kg body weight daily."( [Tauro-ursodeoxycholic acid vs. ursodeoxycholic acid in the dissolution of biliary calculi. Results of a single blind study].
Chiandussi, L; De Micheli, AG; Gallo, V, 1993
)
0.68
" First, it enhances agonist-induced PIC activity towards [3H]PtdInsP and [3H]PtdInsP2 and, secondly, it decreases the potency for GTP[S] stimulation of PIC, thus enhancing the agonist-induced leftward shift of the dose-response curve for GTP[S]."( Effect of deoxycholate on guanine-nucleotide-dependent carbachol stimulation of phosphoinositidase C in mouse brain cortical membranes.
Bas, N; Garcia, A, 1995
)
0.29
"Jejunal and ileal rabbit intestinal segments were separately perfused with bile acid solutions, and dose-response curves were obtained for taurocholate, ursodeoxycholate, chenodeoxycholate, deoxycholate, and their glycoconjugates."( Intestinal absorption of bile acids in the rabbit: different transport rates in jejunum and ileum.
Aldini, R; Biagi, PL; Hrelia, S; Montagnani, M; Roda, A; Roda, E, 1996
)
0.29
" This study showed that amphotericin B should be given at a dosage of 1 mg/kg bw/day for 20 days for Indian kala-azar patients to minimise relapses and prevent development of drug unresponsiveness."( Comparison of regimens of amphotericin B deoxycholate in kala-azar.
Pandey, AK; Sinha, GP; Thakur, CP, 1996
)
0.29
" In addition, both AmBisome regimens reduced hepatosplenic dissemination, and the 10 m/kg dosage fully prevented this complication."( Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
Bakker-Woudenberg, IA; de Marie, S; Leenders, AC; ten Kate, MT; Verbrugh, HA, 1996
)
0.29
" Forty-six patients were assigned to receive Intralipid/amphotericin B at a 50% higher dosage (1 mg/[kg."( Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Aboulker, JP; Aubry, P; Carrière, I; Coulaud, JP; Joly, V; Kawa, E; Larouze, B; Mlika-Cabanne, N; Ndayiragide, A; Yeni, P, 1996
)
0.29
" The optimal dosage of L-nystatin was 5 mg/kg daily on days 1, 2, 4, and 7 (90% survival)."( Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning, DW; Warn, P, 1999
)
0.3
" Thus, in this work, a dose-response study was carried out to investigate the in vitro cytotoxic effect of major unconjugated and tauro- (T) or glyco- (G) conjugated bile acids and to compare this as regards their ability to inhibit DNA synthesis."( Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture.
Marin, JJ; Martinez-Diez, MC; Monte, MJ; Serrano, MA, 2000
)
0.31
"A simple and rapid acid precipitation method has been applied successfully for separating free capsular polysaccharide of Haemophilus influenzae type b (polyribosyl ribitol phosphate, PRP) from PRP tetanus toxoid conjugate (PRP-T) in a final dosage amount of low-level materials."( Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC/PAD following rapid separation by deoxycholate/HCl.
Heller, R; Lamb, DH; Lei, QP; Pietrobon, P, 2000
)
0.31
" However, a 24-hour dosing regimen of AmB may be well tolerated even in these patients."( Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients.
Boehler, A; Dutly, A; Naef, R; Russi, EW; Speich, R; Weder, W, 2002
)
0.31
" Except for the kidneys, the mean concentrations of LNYS in liver, spleen, and lung 24 h after dosing were severalfold lower than those after administration of DAMB (P, <0."( Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.
Alfaro, RM; Groll, AH; King, C; Mickiene, D; Petraitiene, R; Petraitis, V; Piscitelli, SC; Walsh, TJ, 2003
)
0.32
" Dogs were treated twice weekly with an increasing dosage of amphotericin (0."( Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis.
Cortadellas, O,
)
0.13
" In a competitive enzyme-linked immunosorbent assay using DCA-coated microtiter plates, the scFv provided a dose-response curve for free DCA ranging between 2 and 5000 pg/assay."( Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins.
Goto, J; Kato, Y; Kobayashi, N; Mano, N; Ohtoyo, M; Wada, E, 2005
)
0.57
"Recent open label studies have suggested that dosing amphotericin B (AMB) by continuous infusion (CI) may reduce drug-associated infusion reactions and nephrotoxicity."( In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Kontoyiannis, DP; Lewis, RE; Prince, RA; Wiederhold, NP, 2006
)
0.33
" No substantial differences in the rate or extent of AMB killing were observed between rapid infusion or CI dosing and neither regimen produced fungicidal activity in the presence of HSA."( In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Kontoyiannis, DP; Lewis, RE; Prince, RA; Wiederhold, NP, 2006
)
0.33
" In our model, CI and rapid infusion dosing of AMB exhibited similar activity when attempts were made to correct for protein binding that is likely to occur in vivo."( In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Kontoyiannis, DP; Lewis, RE; Prince, RA; Wiederhold, NP, 2006
)
0.33
" A rectal dosage form of CBZ is not commercially available, although it is of particular interest when oral administration is impossible."( Thermally reversible in situ gelling carbamazepine liquid suppository.
El-Kamel, A; El-Khatib, M,
)
0.13
" Three dosage groups (0."( Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Chi, J; Kontoyiannis, DP; Lewis, RE; Prince, RA; Tam, VH; Wiederhold, NP, 2006
)
0.33
"In this study, rational dosing guidelines for amphotericin B-deoxycholate (AmB) are proposed for children."( Amphotericin B dose optimization in children with malignant diseases.
Coakley, JC; Earl, JW; McLachlan, AJ; Nath, CE; Shaw, PJ, 2007
)
0.34
" As illustrated in published reports, a higher dose of L-AmB may be prescribed in the case of unresponsiveness to treatment at normal dosage levels."( Use of high-dose liposomal amphotericin B: efficacy and tolerance.
Adam, A; Garbino, J, 2006
)
0.33
" We propose a new orally active heparin, Db-LHD, in a solid dosage form to effectively prevent DVT and PE."( A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Byun, Y; Kim, CY; Kim, SK; Lee, DY; Moon, HT; Nam, JH, 2007
)
0.34
" This dose-response data may be important clinically as DCA exposure to the oesophagus may be used as a way to identify the 10% of Barrett's oesophagus patients currently progressing to cancer from the 90% of patients who do not progress."( The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.
Alhamdani, A; Baxter, JN; Cronin, J; D'Souza, F; Eltahir, Z; Griffiths, AP; Jenkins, GJ; Rawat, N; Thomas, T, 2008
)
0.71
"A water-insoluble complex between diltiazem HCl and Na deoxycholate was prepared to achieve sustained release dosage forms."( Drug-organic electrolyte complexes as controlled release systems.
Alexander, KS; Fifer, EK; Kim, CJ; Vadlapatla, R, 2009
)
0.35
"The D-AMB-coated PLGA-DMSA nanoparticle showed antifungal efficacy, fewer undesirable effects and a favourable extended dosing interval."( Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
Amaral, AC; Bentes, R; Bocca, AL; Felipe, MS; Lacava, ZG; Morais, PC; Nunes, J; Peixoto, DL; Primo, FL; Ribeiro, AM; Simioni, AR; Tedesco, AC; Titze-de-Almeida, R, 2009
)
0.35
" Significantly fewer patients who received the 3 mg/kg/day dosage of liposomal amphotericin B developed nephrotoxicity, indicated by a doubling of the serum creatinine value, compared with recipients of conventional amphotericin B (P = ."( Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Barker, DE; El-Sadr, W; Graybill, JR; Hamill, RJ; Javaly, K; Johnson, PC; Sobel, JD, 2010
)
0.36
" On the other hand, when the dosage of LMWH-DOCA was reduced to 1mg/kg, its efficacy on anastomosis was not as efficacious in terms of patency."( Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
Al-Hilal, TA; Byun, Y; Eom, JS; Jeon, OC; Koh, KS; Moon, HT; Park, JW, 2010
)
0.36
" After orally administration of PTX-loaded DHC micelles, the bioavailability was threefold compared with that of an orally dosed Taxol®."( Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system.
Dai, Y; Deng, Y; Huo, M; Li, H; Masoud, J; Shi, X; Zhou, J, 2010
)
0.62
"This study was designed to develop a solid oral dosage form of deoxycholic acid (DOCA)-conjugated low-molecular-weight heparin (LMWH) and to evaluate its oral absorption, distribution, and metabolic stability for the prospect of providing an orally bioavailable LMWH."( Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Al-Hilal, TA; Byun, Y; Jeon, OC; Kim, CY; Kim, SK; Lim, KM; Moon, HT; Park, JW, 2011
)
0.83
" This finding may be related to inadequate penetration of amphotericin B lipid products into the kidneys, inappropriate dosing in premature infants, or unknown differences in acuity of illness in infants treated with amphotericin B lipid products."( Antifungal therapy and outcomes in infants with invasive Candida infections.
Ascher, SB; Benjamin, DK; Clark, RH; Cohen-Wolkowiez, M; Moran, C; Smith, PB; Watt, K, 2012
)
0.38
" However, additional studies evaluating different dosing and further time points after treatment are necessary."( Induction of fat cell necrosis in human fat tissue after treatment with phosphatidylcholine and deoxycholate.
Altmeyer, P; Bechara, FG; Hoffmann, K; Jacob, M; Mannherz, HG; Mazur, AJ; Sand, M, 2012
)
0.38
" The primary goal was to investigate the effect of cholate type, particle size and dosage of the liposomes on the hypoglycemic activity and oral bioavailability."( Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.
Guan, P; Hovgaard, L; Lian, R; Lu, Y; Niu, M; Qi, J; Tan, Y; Wu, W, 2012
)
0.38
" In 10-day studies dosing uninfected mice, minor renal tubular changes occurred after AmBisome or Abelcet at 1, 5, or 10 mg/kg with or without cyclophosphamide treatment; nephrosis occurred only with Abelcet in cyclophosphamide-treated mice."( Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Clemons, KV; Schwartz, JA; Stevens, DA, 2012
)
0.38
" These results suggested that the DOMC-FA micelles can prolong blood circulation time and modify the tissue distribution of PTX, and could provide a useful alternative dosage form for intravenous administration of PTX."( Tissue distribution and pharmacokinetics evaluation of DOMC-FA micelles for intravenous delivery of PTX.
Guo, H; Guo, S; Hao, L; Li, C; Wang, F; Zhang, D; Zhang, Q; Zheng, D, 2013
)
0.39
" Remarkably, the dose-response of the natural LPS mixture resembled that of the R-LPS and SR-LPS fractions, supporting that short-chain (R and SR) forms of LPS dominate the innate immune response of human macrophages to LPS in vitro."( Intact rough- and smooth-form lipopolysaccharides from Escherichia coli separated by preparative gel electrophoresis exhibit differential biologic activity in human macrophages.
Brade, H; Lindner, B; Pupo, E; Schromm, AB, 2013
)
0.39
"The dosing differences between nonliposomal and liposomal preparations of amphotericin B can be as high as 50-fold."( Survival after amphotericin B overdose treated with plasmapheresis.
Banerji, S; Heard, KJ; Roussil, TK; Wang, GS, 2013
)
0.39
" Further pharmacokinetic and pharmacodynamic studies of the drug in children could also provide information for rational dosing regimens designed to decrease nephrotoxicity."( Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
Arrizurieta, E; Bes, DF; Rosanova, MT; Sberna, N, 2014
)
0.4
" However, major limitations of LHT7 are its poor oral bioavailability, short half-life, and frequent parenteral dosing schedule."( Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Al-Hilal, TA; Alam, F; Byun, Y; Chung, SW; Kim, HS; Kim, SY; Mahmud, F; Seo, D, 2014
)
0.61
"These observations indicate that naringenin was harmless upon exposure to rat gastrointestinal epithelium, clearly demonstrating the potential use of naturally occurring bioflavonoid as safe and novel pharmaceutical adjuvant in oral dosage forms as P-gp inhibitor."( Safety evaluation of naringenin upon experimental exposure on rat gastrointestinal epithelium for novel optimal drug delivery.
Nanjwade, BK; Patil, PA; Surampalli, G, 2016
)
0.43
" Fewer than one-half of the patients (n=371) received a TDD within the dosing range recommended in the current guidelines."( Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.
Bielicki, J; Doerholt, K; Goossens, H; Lestner, JM; Roilides, E; Sharland, M; Versporten, A; Warris, A, 2015
)
0.42
" Advances in pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial medications have led to improved dosing guidance for neonates."( New antifungal and antiviral dosing.
Monk, HM; Wade, KC, 2015
)
0.42
" A clinical dosage of liposomal amphotericin B of 3 mg/kg/day is predicted to cause complete suppression of galactomannan and (1 → 3)-β-D-glucan levels in the majority of patients."( Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
Al-Nakeeb, Z; Goodwin, J; Hope, WW; Petraitiene, R; Petraitis, V; Walsh, TJ, 2015
)
0.42
" The relative bioavailabilities of CIT-SO high dosage, CIT-SO medium dosage, and CIT-SO low dosage (area under concentration-time curve [AUC]0-∞) compared with that of raw CIT high dosage, CIT medium dosage, and CIT low dosage (AUC0-∞) were 127%, 121%, and 134%, respectively."( Mechanism of enhanced antiosteoporosis effect of circinal-icaritin by self-assembled nanomicelles in vivo with suet oil and sodium deoxycholate.
Feng, L; Jia, X; Jiang, J; Li, J; Sun, E; Zhang, Z, 2015
)
0.42
"We assessed the possibility of changing the route of administration of zoledronic acid to an oral dosage form and its therapeutic efficacy in an estrogen-deficient osteoporosis rat model."( Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
Byun, Y; Jeon, OC; Kim, HS; Park, JW; Seo, DH, 2016
)
0.67
" In vitro, experimental animal models and human clinical trial data are summarized, and novel routes of administration and dosing schedules are discussed."( Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
Bicanic, T; Hope, W; Salim, R; Stone, NR, 2016
)
0.43
" Renal and hepatic markers were raised for Fungizone®-like formulation-treated rats but not for AmB-SDCS formulations following 7 days of regular dosing by intratracheal instillation."( Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
Javed, I; Nopparat, J; Srichana, T; Usman, F, 2020
)
0.56
" These results of SMF correction suggest that significant benefit can be obtained with proper dosing at the initial visit."( Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Fabi, SG; Greene, R; Karavan, M; Zarbafian, M, 2020
)
0.56
" The concentration and dose injected by the patient resulted in a 10-fold overdose of deoxycholic acid in comparison to the FDA-recommended dosing for the approved indication."( Hemolysis after subcutaneous deoxycholic acid overdose.
Feldman, R; O'Keefe, M; Sharpe, A; Theobald, J; Windsor, K, 2022
)
1.24
"In this study, we developed oral pemetrexed (PMX) for metronomic dosing to enhance antitumor immunity."( Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity.
Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Maharjan, R; Pangeni, R; Park, JW; Subedi, L, 2021
)
0.62
" In the colistin:SDCS treatment groups, the dosage was 15 mg/kg/day colistin equivalent; all mice were treated for 7 successive days."( In vivo evaluation of nephrotoxicity and neurotoxicity of colistin formulated with sodium deoxycholate sulfate in a mice model.
Bintang, MAKM; Nopparat, J; Srichana, T, 2023
)
0.91
" SMF was assessed at baseline and after dosing with newly developed scales, namely the Clinician Chin Assessment Tool (C-CAT) and Subject Chin Assessment Tool (S-CAT)."( Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction.
Ablon, G; Biesman, B; Cohen, J; Dayan, S; Downie, J; Fabi, S; Fagien, S; Gold, M; Gueta, R; Jones, D; Shamban, A; Shridharani, SM; Walker, P; Yoelin, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
bile acidAny member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration.
dihydroxy-5beta-cholanic acidA hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.
C24-steroidA steroid compound with a structure based on a 24-carbon (cholane) skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (14)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Bile acid and bile salt metabolism3171
Recycling of bile acids and salts1810
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761
Inner Membrane Transport7862
Drug induction of bile acid pathway025

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686979
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency25.11890.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency2.90930.004611.374133.4983AID624297
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)100.00000.00000.43746.4300AID1277414; AID1277417
Ileal sodium/bile acid cotransporterHomo sapiens (human)Ki6.30003.30006.400010.0000AID681332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, STEROID DELTA-ISOMERASEPseudomonas putidaKd45.740045.740045.740045.7400AID977611
Vitamin D3 receptorHomo sapiens (human)EC50 (µMol)150.00000.00000.14232.1400AID1277413; AID1277415
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)1.25000.02372.52598.9000AID324923
Bile acid receptorHomo sapiens (human)EC50 (µMol)47.50000.00401.419110.0000AID1351287; AID662692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (99)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1412057Antiangiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as abnormality in vasculature in developing embryos at 25 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID524265Antibacterial activity against Escherichia coli NKE159 harboring deletion mutation in acrB, cpxAR protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID524262Antibacterial activity against Escherichia coli NKE155 harboring deletion mutation in acrB protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1351288Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay relative to CDCA2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID571883Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1487656Selectivity index, ratio of IC50 for human HFF-3 cells to IC50 for human A549 cells2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID1412073Cytotoxicity against HUVEC assessed as reduction in cell viability at 6.25 to 100 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID679968TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, DCA: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID572059Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524389Antibacterial activity against Escherichia coli NKE1367 harboring deletion mutation in acrB, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524266Antibacterial activity against Escherichia coli NKE128 harboring deletion mutation in acrB and tolC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1767078Agonist activity at TGR5 (unknown origin) transfected in HEK293 cells assessed as increase in intracellular calcium level at 0.1 mM in presence of Galphaq inhibitor, UBO-QIC and in absence of extracellular calcium by Fura-2AM dye based fluorometric analys2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID524260Antibacterial activity against Escherichia coli NKE96 harboring deletion mutation in acrB protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1412040Toxicity in zebrafish embryo assessed as reduction in embryo survival up to 50 uM2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1767076Agonist activity at TGR5 (unknown origin) transfected in HEK293 cells assessed as increase in intracellular calcium level at 0.33 mM in presence of Galphaq inhibitor, UBO-QIC and in absence of extracellular calcium by Fura-2AM dye based fluorometric analy2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID729025Binding affinity to Pseudomonas putida KSI by isothermal titration calorimetry2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Incorporation of rapid thermodynamic data in fragment-based drug discovery.
AID1412050Antiangiogenic activity in HUVEC assessed as inhibition of endothelial tube formation at 25 uM after overnight incubation by inverted microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID571885Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524391Antibacterial activity against Escherichia coli NKE1368 harboring deletion mutation in acrB, acrD and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID681332TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID572058Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID368423Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1277420Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 18 hrs by CellTiter-Glo luminescence assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1487655Antiproliferative activity against human KB3-1 cells after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID524388Antibacterial activity against Escherichia coli NKE1366 harboring deletion mutation in acrB and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID679958TP_TRANSPORTER: uptake of Deoxycholate at 1 uM in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID729024Binding affinity to Pseudomonas putida KSI by surface plasmon resonance analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Incorporation of rapid thermodynamic data in fragment-based drug discovery.
AID679836TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 5 uM, Deoxycholate: 100 uM) in NTCP-expressing HeLa cells1999The Journal of pharmacology and experimental therapeutics, Dec, Volume: 291, Issue:3
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.
AID1277417Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1412062Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as sprouting of vessels at 6.25 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID572060Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID534112Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm19802008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1487657Selectivity index, ratio of IC50 for human HFF-3 cells to IC50 for human HepG2 cells2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID368419Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID679994TP_TRANSPORTER: uptake of Deoxycholate at a concentration of 1 u M in NTCP-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID571884Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524261Antibacterial activity against Escherichia coli NKE154 harboring vector expressing acrB deletion mutant2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1487662Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID1487654Antiproliferative activity against human A549 cells after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID368424Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID680372TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, Deoxycholate: 72 uM) in Ntcp-expressing COS-7 cells2002Bioscience, biotechnology, and biochemistry, May, Volume: 66, Issue:5
Characterization of cloned mouse Na+/taurocholate cotransporting polypeptide by transient expression in COS-7 cells.
AID1233565Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 100 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID368422Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID679473TP_TRANSPORTER: Western in vitro, primary human hepatocyte2001The Journal of biological chemistry, Oct-19, Volume: 276, Issue:42
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.
AID534109Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm05272008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1487659Selectivity index, ratio of IC50 for human HFF-3 cells to IC50 for human HuTu 80 cells2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID524382Antibacterial activity against Escherichia coli NKE160 harboring deletion mutation in acrB protein and vector expressing tolC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID679946TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.72 uM, Deoxycholate: a 100-fold excess) in isolated mouse ileocytes1999Journal of biochemistry, Apr, Volume: 125, Issue:4
Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter.
AID657096Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scin2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID524390Antibacterial activity against Escherichia coli NKE1316 harboring deletion mutation in acrB, acrD and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID534108Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1327991Antiproliferative activity against human ES2 cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID1487660Cytotoxicity against human HFF-3 cells after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1767079Induction of intracellular calcium level in human HEK293 cells at 0.1 mM in presence of Galphaq inhibitor, UBO-QIC and in absence of extracellular calcium by Fura-2AM dye based fluorometric analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1233569Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 100 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID524383Antibacterial activity against Escherichia coli NKE161 harboring deletion mutation in acrB protein, vector expressing tolC gene and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID572061Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC00372009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID534107Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1767067Cytotoxicity against human HEK293 cells transfected with TGR5 assessed as reduction in cell viability at 0.33 to 0.5 mM measured after 2.5 hrs by MTS assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID662692Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1412061Pro-angiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as thickening of vessels at 6.25 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID524263Antibacterial activity against Escherichia coli NKE127 harboring deletion mutation in acrB and cpxAR protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1327989Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID524385Antibacterial activity against Escherichia coli NKE156 harboring deletion mutation in acrB protein and vector expressing acrD gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID534106Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1327990Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel 3,4-seco bile acid diamides as selective anticancer proliferation and migration agents.
AID1767077Induction of intracellular calcium level in human HEK293 cells at 0.33 mM in presence of Galphaq inhibitor, UBO-QIC and in absence of extracellular calcium by Fura-2AM dye based fluorometric analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1233568Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 20 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1412056Toxicity in Tg(fli:eGFP) zebrafish embryo assessed as embryo death at 25 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID524386Antibacterial activity against Escherichia coli NKE157 harboring deletion mutation in acrB, acrD protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1412058Antiangiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as vascular modification by measuring formation of irregular pattern of branches at 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1487661Antiproliferative activity against human HuTu 80 cells after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID524392Antibacterial activity against Escherichia coli NKE1369 harboring deletion mutation in acrB, acrD, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID368418Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1233566Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 20 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1767075Induction of intracellular calcium level in human HEK293 cells at 0.1 to 0.33 mM in absence of extracellular calcium by Fura-2AM dye based fluorometric analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID572062Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID571882Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1767074Agonist activity at TGR5 (unknown origin) transfected in HEK293 cells assessed as increase in intracellular calcium level at 0.1 to 0.33 mM in absence of extracellular calcium by Fura-2AM dye based fluorometric analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID524393Antibacterial activity against Escherichia coli NKE1359 harboring deletion mutation in acrB protein and plasmid expressing BADnlpE gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1277415Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1487658Selectivity index, ratio of IC50 for human HFF-3 cells to IC50 for human KB3-1 cells2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Novel derivatives of deoxycholic acid bearing aliphatic or cyclic diamine moieties at the C-3 position: Synthesis and evaluation of anti-proliferative activity.
AID1233570Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 20 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1412043Cytotoxicity against HUVEC assessed as reduction in cell death up to 12.5 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1277414Antagonist activity against VDR-LBD (unknown origin) expressed in Escherichia coli assessed as inhibition of VDR agonist LG190178-induced SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1767066Cytotoxicity against human HEK293 cells transfected with TGR5 assessed as reduction in cell viability at 0.67 mM measured after 2.5 hrs by MTS assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Marine Bile Natural Products as Agonists of the TGR5 Receptor.
AID524394Antibacterial activity against Escherichia coli NKE1355 harboring deletion mutation in acrB protein and plasmid expressing BAD gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1233567Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 100 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID679971TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, DCA: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID534110Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID1277413Agonist activity at VDR-LBD (unknown origin) expressed in Escherichia coli assessed as SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID524264Antibacterial activity against Escherichia coli NKE158 harboring deletion mutation in acrB protein and vector expressing cpxAR gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID534111Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID524384Antibacterial activity against Escherichia coli NKE126 harboring deletion mutation in acrB and acrD protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID368421Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1351287Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID524387Antibacterial activity against Escherichia coli NKE1365 harboring deletion mutation in acrB and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID368420Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1345827Human FPR1 (Formylpeptide receptors)2002Biochemical pharmacology, Feb-01, Volume: 63, Issue:3
Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants.
AID1346437Human GPBA receptor (Bile acid receptor)2002Biochemical and biophysical research communications, Nov-15, Volume: 298, Issue:5
Identification of membrane-type receptor for bile acids (M-BAR).
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2000The Journal of biological chemistry, Dec-29, Volume: 275, Issue:52
Detection of large pKa perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymes.
AID1811Experimentally measured binding affinity data derived from PDB2000The Journal of biological chemistry, Dec-29, Volume: 275, Issue:52
Detection of large pKa perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymes.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,021)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902551 (50.81)18.7374
1990's629 (12.53)18.2507
2000's683 (13.60)29.6817
2010's909 (18.10)24.3611
2020's249 (4.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 86.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index86.09 (24.57)
Research Supply Index8.59 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index162.91 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (86.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials172 (3.30%)5.53%
Reviews177 (3.39%)6.00%
Case Studies121 (2.32%)4.05%
Observational9 (0.17%)0.25%
Other4,737 (90.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (44)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil [NCT01310738]Phase 4378 participants (Actual)Interventional2011-02-28Terminated(stopped due to DSMB recommendation based on programmed interim analysis.)
Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat [NCT04054011]Early Phase 115 participants (Actual)Interventional2019-07-05Completed
Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Post Marketing Surveillance Study in Korea [NCT03691415]71 participants (Actual)Observational2018-09-07Terminated(stopped due to Study discontinued due to business decisions.)
A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis [NCT02136030]84 participants (Anticipated)Interventional2011-02-28Recruiting
Long-term, Follow-up Study of Subjects Who Completed Phase III Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT03682471]201 participants (Actual)Observational2012-02-14Completed
Comparison of the Efficacy Between Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for the Treatment of Upper Back Fat: a Prospective Randomized Controlled Pilot Study. [NCT03284034]34 participants (Anticipated)Interventional2017-11-27Active, not recruiting
A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling [NCT03361176]Phase 430 participants (Actual)Interventional2018-03-26Completed
Fat Reduction in the Submental Area - a Sequential Treatment Approach With CoolMini and KYBELLA® [NCT03510598]Phase 416 participants (Actual)Interventional2018-03-27Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (SMF) Using Magnetic Resonance Imaging (MRI) and a Battery of C [NCT01032889]Phase 2129 participants (Actual)Interventional2009-12-31Completed
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT01294644]Phase 3360 participants (Actual)Interventional2011-01-31Completed
The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock [NCT05642624]20 participants (Actual)Observational2019-02-28Completed
Metabolic And Structural Effects Of Phosphatidylcholine And Deoxycholate Injections On Subcutaneous Fat [NCT00757081]20 participants (Actual)Interventional2008-06-30Completed
Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (t [NCT00696969]Phase 3634 participants (Actual)Interventional2008-06-30Completed
A Randomized, Double-blind Comparison Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat [NCT03241563]Phase 420 participants (Actual)Interventional2016-04-30Completed
A Randomized, Double-Blinded, Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal [NCT00851747]18 participants (Actual)Interventional2009-02-28Terminated
Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children [NCT01032187]Phase 4101 participants (Actual)Interventional2007-10-31Completed
"Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the Anterior and Posterior Aspect of the Axilla Bra Strap Fat" [NCT04089722]Phase 422 participants (Actual)Interventional2019-07-26Completed
A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis [NCT00815516]Phase 330 participants (Actual)Interventional2013-02-28Terminated(stopped due to It was decided to discontinue the study due to insufficient recruitment.)
The Effect and Safety of Three Initial Introduction Treatments on HIV-infected Patients With Cryptococcal Meningitis: A Multi-center, Random and Prospective Study [NCT04072640]Early Phase 1120 participants (Anticipated)Interventional2021-01-25Active, not recruiting
A Randomized Controlled Trial of Combined Inhalational With Intravenous Amphotericin B in Comparison With Intravenous Amphotericin B Alone for Treatment of Pulmonary Mucormycosis [NCT04502381]Phase 230 participants (Actual)Interventional2020-07-01Completed
A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis [NCT00885703]Phase 1/Phase 2168 participants (Actual)Interventional2010-04-16Completed
Phase 1-2, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) for the Reduction of Subcutaneous Fat in the Submental Area [NCT00618722]Phase 1/Phase 285 participants (Actual)Interventional2007-08-31Completed
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas [NCT00608842]Phase 262 participants (Actual)Interventional2007-11-30Completed
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Subme [NCT00618618]Phase 273 participants (Actual)Interventional2008-04-30Completed
A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis [NCT00628719]Phase 3400 participants (Anticipated)Interventional2008-02-29Completed
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas [NCT04730583]Phase 120 participants (Anticipated)Interventional2021-06-02Active, not recruiting
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT01305577]Phase 3363 participants (Actual)Interventional2010-12-31Completed
A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) [NCT00523965]Phase 3624 participants (Anticipated)Interventional2007-09-30Completed
A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS [NCT00002742]Phase 30 participants Interventional1996-01-31Completed
Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis [NCT00310505]1,500 participants Interventional2003-01-31Completed
Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. [NCT00361517]Phase 347 participants (Actual)Interventional2006-06-01Completed
A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid) Injection for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Grade 1 or [NCT02035267]Phase 393 participants (Actual)Interventional2014-01-31Completed
Kybella for the Treatment of Flank Fat (FF) [NCT04841551]Phase 410 participants (Actual)Interventional2021-07-22Completed
An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients [NCT00003031]Phase 3212 participants (Anticipated)Interventional1997-06-30Completed
CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes) [NCT02438813]1,029 participants (Actual)Observational [Patient Registry]2015-05-11Completed
A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months o [NCT01945281]Phase 251 participants (Actual)Interventional2014-01-15Terminated(stopped due to Operational feasibility with low recruitment due to changing epidemiology of disease)
A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid) Injection for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age [NCT02123134]Phase 355 participants (Actual)Interventional2014-04-30Completed
Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas [NCT06120036]Phase 120 participants (Anticipated)Interventional2022-12-06Recruiting
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT01546142]Phase 3516 participants (Actual)Interventional2012-03-31Completed
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas [NCT06132165]Phase 130 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Multicenter, Open-label Study of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT01426373]Phase 3165 participants (Actual)Interventional2011-08-31Completed
A Single Center, Double-blind, Parallel-group, Two Factor Patient-Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT02007434]Phase 384 participants (Actual)Interventional2013-12-31Completed
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area [NCT01542034]Phase 3506 participants (Actual)Interventional2012-02-29Completed
Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of the Pharmacokinetics, Safety, and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipo [NCT00422188]Phase 116 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00608842 (7) [back to overview]Number of Participants With Positive Histopathology Results at Week 20
NCT00608842 (7) [back to overview]Number of Participants With Clinically Significant Changes in Vital Signs or Weight
NCT00608842 (7) [back to overview]Number of Participants With Adverse Events (AEs)
NCT00608842 (7) [back to overview]Number of Participants With Newly Occurring or Worsening Biochemistry/Hematology/Urinalysis Abnormalities
NCT00608842 (7) [back to overview]Number of Participants With Positive Histopathology Results at Screening
NCT00608842 (7) [back to overview]Percent Change From Baseline in the Sum of the Areas of All Treated Lipomas
NCT00608842 (7) [back to overview]Percentage of Participants With Complete Clearance or ≥ 75% Clearance
NCT00618618 (10) [back to overview]Number of Participants With Adverse Events
NCT00618618 (10) [back to overview]Visual Analogue Scale Pain Intensity Rating
NCT00618618 (10) [back to overview]Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Weight, Vital Signs, and Physical Examinations
NCT00618618 (10) [back to overview]Change From Baseline in Subject Satisfaction With Appearance Rating Scale
NCT00618618 (10) [back to overview]Change From Baseline in Submental Fat (SMF) Rating Scale Score
NCT00618618 (10) [back to overview]Change From Baseline in the Cervicomental Angle
NCT00618618 (10) [back to overview]Percentage of Participants With a Response in the Subject Global Improvement Rating
NCT00618618 (10) [back to overview]Percentage of Participants With an SMF Response
NCT00618618 (10) [back to overview]Change From Baseline in Skin Laxity Rating
NCT00618618 (10) [back to overview]Change From Baseline to Each Visit in Submental Fat (SMF) Rating Scale Score
NCT00618722 (7) [back to overview]Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Weight, Vital Signs, and Physical Examinations
NCT00618722 (7) [back to overview]Percentage of Participants With a Response in the Subject Global Improvement Rating
NCT00618722 (7) [back to overview]Change From Baseline in the Cervicomental Angle
NCT00618722 (7) [back to overview]Change From Baseline in Submental Fat (SMF) Rating Scale Score
NCT00618722 (7) [back to overview]Change From Baseline in Subject Satisfaction With Appearance Rating Scale
NCT00618722 (7) [back to overview]Number of Participants With Adverse Events
NCT00618722 (7) [back to overview]Change From Baseline in Skin Laxity Rating
NCT00815516 (13) [back to overview]Fungal-free Survival at End of Study Drug Therapy in Infants With End-organ Dissemination
NCT00815516 (13) [back to overview]Fungal-free Survival One Week After Last Dose of Study Drug in Infants With End-organ Dissemination
NCT00815516 (13) [back to overview]Follow-up Status for Infants With End-organ Assessments
NCT00815516 (13) [back to overview]Percentage of Participants With Recurrent Fungal Infections
NCT00815516 (13) [back to overview]Time to Mycological Clearance of Invasive Candidiasis
NCT00815516 (13) [back to overview]Time to Positive Clinical Response
NCT00815516 (13) [back to overview]Clinical Response at the End of Study Drug Therapy
NCT00815516 (13) [back to overview]Clinical Response One Week After Last Dose of Study Drug
NCT00815516 (13) [back to overview]Percentage of Participants With Emergent Fungal Infections
NCT00815516 (13) [back to overview]Mycological Response at End of Study Drug Therapy
NCT00815516 (13) [back to overview]Mycological Response One Week After Last Dose of Study Drug
NCT00815516 (13) [back to overview]Plasma Micafungin Concentration
NCT00815516 (13) [back to overview]Fungal-free Survival
NCT00885703 (10) [back to overview]Kaplan Meier (KM) Proportion of Participant Mortality
NCT00885703 (10) [back to overview]Length of Hospitalization
NCT00885703 (10) [back to overview]Number of Participants With CNS IRIS
NCT00885703 (10) [back to overview]Number of Participants With Progression of Symptoms
NCT00885703 (10) [back to overview]Number of Participants With Grade 3 and 4 Adverse Events
NCT00885703 (10) [back to overview]Results of Functional Status Evaluation
NCT00885703 (10) [back to overview]Categorized Quantitative Culture Results
NCT00885703 (10) [back to overview]Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B
NCT00885703 (10) [back to overview]Change in Log10 Quantitative CSF Culture Results
NCT00885703 (10) [back to overview]Results of the Neurological Examination
NCT01032889 (5) [back to overview]Change From Baseline in Submental Fat Volume
NCT01032889 (5) [back to overview]Change From Baseline in Submental Fat Thickness
NCT01032889 (5) [back to overview]Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
NCT01032889 (5) [back to overview]Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
NCT01032889 (5) [back to overview]Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores
NCT01294644 (8) [back to overview]Change From Baseline in Submental Fat Thickness
NCT01294644 (8) [back to overview]Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
NCT01294644 (8) [back to overview]Percentage of Participants With a CR-SMFRS 2-grade Response
NCT01294644 (8) [back to overview]Percentage of Participants With a Subject Self Rating Scale (SSRS) Response
NCT01294644 (8) [back to overview]Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)
NCT01294644 (8) [back to overview]Change From Baseline in Self-rating of Attractiveness
NCT01294644 (8) [back to overview]Change From Baseline in SSRS Scores
NCT01294644 (8) [back to overview]Change From Baseline in CR-SMFRS Score
NCT01305577 (8) [back to overview]Change From Baseline in Submental Fat Thickness
NCT01305577 (8) [back to overview]Change From Baseline in CR-SMFRS Scores
NCT01305577 (8) [back to overview]Change From Baseline in SSRS Scores
NCT01305577 (8) [back to overview]Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
NCT01305577 (8) [back to overview]Percentage of Participants With a CR-SMFRS 2-grade Response
NCT01305577 (8) [back to overview]Percentage of Participants With a Subject Self Rating Scale (SSRS) Response
NCT01305577 (8) [back to overview]Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)
NCT01305577 (8) [back to overview]Change From Baseline in Self-rating of Attractiveness
NCT01426373 (12) [back to overview]Percentage of Participants Who Achieved a Composite 1-grade Response
NCT01426373 (12) [back to overview]Percent Change From Baseline in Submental Fat Thickness
NCT01426373 (12) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01426373 (12) [back to overview]Mean Change From Baseline in Subject Self Rating Scale (SSRS)
NCT01426373 (12) [back to overview]Mean Change From Baseline in Self-rating of Attractiveness
NCT01426373 (12) [back to overview]Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
NCT01426373 (12) [back to overview]Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
NCT01426373 (12) [back to overview]Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
NCT01426373 (12) [back to overview]Response to Subject Global Questions
NCT01426373 (12) [back to overview]Percentage of Participants Who Achieved a Composite 2-grade Response
NCT01426373 (12) [back to overview]Change From Baseline in Line Drawing Assessment
NCT01426373 (12) [back to overview]Change From Baseline in Submental Skin Laxity Grade (SMSLG)
NCT01542034 (4) [back to overview]Percentage of Participants With a Magnetic Resonance Imaging (MRI) Response
NCT01542034 (4) [back to overview]Percentage of Participants Who Achieved a Composite 1-grade Response
NCT01542034 (4) [back to overview]Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
NCT01542034 (4) [back to overview]Percentage of Participants Who Achieved a Composite 2-grade Response
NCT01546142 (4) [back to overview]Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
NCT01546142 (4) [back to overview]Percentage of Participants With a Magnetic Resonance Imaging (MRI) Response
NCT01546142 (4) [back to overview]Percentage of Participants Who Achieved a Composite 2-grade Response
NCT01546142 (4) [back to overview]Percentage of Participants Who Achieved a Composite 1-grade Response
NCT01945281 (3) [back to overview]Number of Participants With an Adverse Event (AE)
NCT01945281 (3) [back to overview]Percentage of Participants With Fungal-free Survival Through the 2-week Post-therapy Period
NCT01945281 (3) [back to overview]Percentage of Participants With Fungal-free Survival Through the End of Study Treatment
NCT02007434 (11) [back to overview]Change From Baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02007434 (11) [back to overview]Change From Baseline in Pain Visual Analog Scale Scores
NCT02007434 (11) [back to overview]Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02007434 (11) [back to overview]Change From Baseline in Subject Self Rating Scale (SSRS)
NCT02007434 (11) [back to overview]Change From Baseline in Submental Skin Laxity Grades (SMSLG)
NCT02007434 (11) [back to overview]Bruising Grading Scale Scores
NCT02007434 (11) [back to overview]Swelling Grading Scale Scores
NCT02007434 (11) [back to overview]Change From Baseline in Pain Assessment Using McGill Pain Questionnaire
NCT02007434 (11) [back to overview]Patient Experience Questions
NCT02007434 (11) [back to overview]Change From Baseline in Submental Fat Thickness
NCT02007434 (11) [back to overview]Induration Grading Scale Scores
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02035267 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
NCT02035267 (7) [back to overview]Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02123134 (7) [back to overview]Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
NCT02123134 (7) [back to overview]Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02438813 (7) [back to overview]Change From Baseline in the Submental Skin Laxity Scale (SMSLG)
NCT02438813 (7) [back to overview]Change From Baseline in the Subject Self Rating Scale (SSRS)
NCT02438813 (7) [back to overview]Change From Baseline in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
NCT02438813 (7) [back to overview]Change From Baseline in the Patient Self-Perception of Age (SPA)
NCT02438813 (7) [back to overview]Change From Baseline in the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
NCT02438813 (7) [back to overview]Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
NCT02438813 (7) [back to overview]Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
NCT03510598 (5) [back to overview]The Proportion of Subjects for Whom a 2-grade Improvement Was Recorded Using the CR-SMFRS From Baseline to Final Follow-uo Visit.
NCT03510598 (5) [back to overview]The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When Compared to the Baseline Grade.
NCT03510598 (5) [back to overview]The Number of Device, Drug or Procedure-related Adverse Events.
NCT03510598 (5) [back to overview]Subject Satisfaction as Measured by a Comparison of Baseline and 12-weeks Post-final Treatment of Completed Subject Self-Rating Scales (SSRS).
NCT03510598 (5) [back to overview]Change in Submental Fat Layer Thickness as Measured by Ultrasound.
NCT04054011 (5) [back to overview]Number of Participants With Adverse Events
NCT04054011 (5) [back to overview]Percent Accuracy by Three Blinded Physicians in Correctly Identifying Before-and-after Photographs
NCT04054011 (5) [back to overview]Change in Thigh Gap
NCT04054011 (5) [back to overview]Upper Inner Thigh Skin Fold Thickness Change
NCT04054011 (5) [back to overview]Thigh Circumference Change

Number of Participants With Positive Histopathology Results at Week 20

After the completion of all tests and procedures scheduled for week 20, participants with treated lipomas that remained palpable could have their treated lipomas excised. (NCT00608842)
Timeframe: Week 20

,,,
Interventionparticipants (Number)
Acute inflammationChronic inflammationFibrosis/scarringHemorrhageMature adipose tissueNecrosis
Deoxycholic Acid 1%3101351514
Deoxycholic Acid 2%2121251313
Deoxycholic Acid 4%1131461514
Placebo0062163

[back to top]

Number of Participants With Clinically Significant Changes in Vital Signs or Weight

(NCT00608842)
Timeframe: Up to 24 weeks

Interventionparticipants (Number)
Deoxycholic Acid 1%0
Deoxycholic Acid 2%0
Deoxycholic Acid 4%0
Placebo0

[back to top]

Number of Participants With Adverse Events (AEs)

"Severity of AEs was determined using the following scale:~Mild: The participant was aware of a sign or symptom, but it was easily tolerated; Moderate: Discomfort or interference with usual activity; Severe: Incapacitating, with inability to engage in usual activity. The investigator determined the relationship of each AE to the administration of study material by answering the question: Was there a reasonable possibility that the event may have been caused by treatment with study material? A serious AE was an event that constituted a significant medical hazard or side effect, regardless of the investigator's or sponsor's opinion regarding relatedness to study material. Serious AEs included any event that was fatal or life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other significant medical hazard." (NCT00608842)
Timeframe: Up to 24 weeks

,,,
Interventionparticipants (Number)
Any adverse eventAny treatment-related adverse eventAny serious adverse eventAny severe adverse eventAny adverse event leading to drug discontinuation
Deoxycholic Acid 1%126111
Deoxycholic Acid 2%139010
Deoxycholic Acid 4%148123
Placebo127000

[back to top]

Number of Participants With Newly Occurring or Worsening Biochemistry/Hematology/Urinalysis Abnormalities

An abnormality is defined as a value outside the limits of the expanded normal range/notable range. (NCT00608842)
Timeframe: 24 weeks

,,,
Interventionparticipants (Number)
Blood triglyceridesAlanine transaminaseAspartate aminotransferaseAlkaline phosphataseUrinalysis - Glucose
Deoxycholic Acid 1%00000
Deoxycholic Acid 2%00000
Deoxycholic Acid 4%11111
Placebo00000

[back to top]

Number of Participants With Positive Histopathology Results at Screening

A needle core tissue sample biopsy was performed at screening for all treated lipomas. (NCT00608842)
Timeframe: Screening (prior to randomization)

,,,
Interventionparticipants (Number)
Acute inflammationChronic inflammationFibrosis/scarringHemorrhageMature adipose tissueNecrosis
Deoxycholic Acid 1%0000110
Deoxycholic Acid 2%0000110
Deoxycholic Acid 4%1012130
Placebo0001130

[back to top]

Percent Change From Baseline in the Sum of the Areas of All Treated Lipomas

Percent change from baseline was calculated as the baseline total lipoma area - postbaseline total lipoma area / baseline total lipoma area * 100. A positive change indicates a reduction in size. (NCT00608842)
Timeframe: Baseline and week 12 (last treatment session), week 16 (4 weeks after last treatment), and week 20 (8 weeks after last treatment)

,,,
Interventionpercent change (Mean)
Week 12Week 16Week 20
Deoxycholic Acid 1%41.243.950.1
Deoxycholic Acid 2%28.523.325.9
Deoxycholic Acid 4%18.020.035.9
Placebo38.532.136.7

[back to top]

Percentage of Participants With Complete Clearance or ≥ 75% Clearance

"At randomization 1 to 3 lipomas were selected for treatment. Lipomas were measured in 3 dimensions (longest length, perpendicular width, and height if possible) using digital calipers.~Complete clearance indicates target lipoma(s) not present or detectable, and ≥ 75% clearance is defined as a ≥ 75% reduction from baseline in the area of target lipoma(s).~For participants with > 1 target lipoma, the total area of all target lipomas was used in the calculation of response." (NCT00608842)
Timeframe: Baseline and week 20 (8 weeks after last dose)

,,,
Interventionpercentage of participants (Number)
Complete Clearance≥ 75% Cleared
Deoxycholic Acid 1%0.013.3
Deoxycholic Acid 2%0.06.7
Deoxycholic Acid 4%7.114.3
Placebo0.011.8

[back to top]

Number of Participants With Adverse Events

"The investigator determined the relationship of each adverse event to the administration of study drug.~Severity of adverse events was determined using the following scale:~Mild: The participant is aware of a sign or symptom, but it is easily tolerated~Moderate: Discomfort or interference with usual activity~Severe: Incapacitating, with inability to engage in usual activity.~A serious AE (SAE) was defined as an event that may constitute a significant medical hazard or side-effect, regardless of the investigator or sponsor's opinion regarding relatedness to study material. Serious events included, but were not limited to, any event that:~was fatal~was life-threatening~required inpatient hospitalization or prolongation of existing hospitalization~resulted in persistent or significant disability/incapacity~was a congenital anomaly/birth defect~other significant medical hazard" (NCT00618618)
Timeframe: From the first dose of study drug until 12 weeks after the last dose (up to 24 weeks after first treatment).

,,,
Interventionparticipants (Number)
Any adverse eventAdverse event associated with treatment areaStudy drug-related adverse eventStudy drug-related severe adverse eventSerious adverse eventDiscontinued due to adverse eventDeaths
0Deoxycholic Acid Injection 0.4 mL/1.0 cm2020205000
Deoxycholic Acid Injection 0.2 mL/0.7 cm2424246020
Deoxycholic Acid Injection 0.2 mL/1.0 cm1313130111
Pooled Placebo1414140000

[back to top]

Visual Analogue Scale Pain Intensity Rating

Participants rated pain associated with the submental area on a 100 mm horizontal axis ranging from 0 (no pain) to 100 (most severe pain possible) (NCT00618618)
Timeframe: Approximately 60 minutes after completion of each treatment session at Week 0, Week 4, Week 8 and Week 12

,,,
Interventionunits on a scale (Mean)
Treatment 1 (N=24, 12, 20, 14)Treatment 2 (N=19, 10, 16, 14)Treatment 3 (N=17, 10, 16, 13)Treatment 4 (N=14, 10, 15, 14)
Deoxycholic Acid Injection 0.2 mL/0.7 cm33.027.926.514.0
Deoxycholic Acid Injection 0.2 mL/1.0 cm25.838.219.213.7
Deoxycholic Acid Injection 0.4 mL/1.0 cm41.931.122.619.0
Pooled Placebo17.124.920.716.7

[back to top]

Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Weight, Vital Signs, and Physical Examinations

(NCT00618618)
Timeframe: From the first dose of study drug until 12 weeks after the last dose (up to 24 weeks after first treatment).

,,,
Interventionparticipants (Number)
Laboratory ValuesWeightVital SignsPhysical Examinations
Deoxycholic Acid Injection 0.2 mL/0.7 cm3000
Deoxycholic Acid Injection 0.2 mL/1.0 cm0000
Deoxycholic Acid Injection 0.4 mL/1.0 cm2010
Pooled Placebo0000

[back to top]

Change From Baseline in Subject Satisfaction With Appearance Rating Scale

"The Subject Satisfaction with Appearance Rating Scale assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.~A positive change from Baseline indicates improvement." (NCT00618618)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 0.2 mL/0.7 cm3.5
Deoxycholic Acid Injection 0.2 mL/1.0 cm4.3
Deoxycholic Acid Injection 0.4 mL/1.0 cm2.8
Pooled Placebo1.8

[back to top]

Change From Baseline in Submental Fat (SMF) Rating Scale Score

"The SMF rating scale score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~A negative change from Baseline indicates improvement." (NCT00618618)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 0.2 mL/0.7 cm-1.0
Deoxycholic Acid Injection 0.2 mL/1.0 cm-1.2
Deoxycholic Acid Injection 0.4 mL/1.0 cm-0.8
Pooled Placebo-0.4

[back to top]

Change From Baseline in the Cervicomental Angle

The cervicomental angle was measured using a profile view photograph obtained at each visit. A goniometer was used to determine the angle. Cervicomental angle measurements less than 80 degrees are excluded, due to error in measurement. (NCT00618618)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventiondegrees (Mean)
Deoxycholic Acid Injection 0.2 mL/0.7 cm-5.0
Deoxycholic Acid Injection 0.2 mL/1.0 cm-1.5
Deoxycholic Acid Injection 0.4 mL/1.0 cm-1.5
Pooled Placebo-2.7

[back to top]

Percentage of Participants With a Response in the Subject Global Improvement Rating

"Participants were asked to rate their total improvement or worsening in the appearance and physical feeling of their chin and neck area since before they received study treatment, whether or not they believed it was due to study treatment or to any other cause.~0 = Very much worse, 1 = Much worse, 2 = Minimally worse, 3 = No change, 4 = Minimally improved, 5 = Much improved, 6 = Very much improved.~Response is defined as any improvement, ie, a global improvement rating of 4, 5, or 6." (NCT00618618)
Timeframe: 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 0.2 mL/0.7 cm95.5
Deoxycholic Acid Injection 0.2 mL/1.0 cm90.0
Deoxycholic Acid Injection 0.4 mL/1.0 cm80.0
Pooled Placebo57.1

[back to top]

Percentage of Participants With an SMF Response

Response is defined as a participant with at least a 1-grade improvement in SMF Rating Scale score at Week 16 from Baseline. The SMF rating scale score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. (NCT00618618)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 0.2 mL/0.7 cm81.8
Deoxycholic Acid Injection 0.2 mL/1.0 cm90.0
Deoxycholic Acid Injection 0.4 mL/1.0 cm60.0
Pooled Placebo35.7

[back to top]

Change From Baseline in Skin Laxity Rating

"Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale:~1 = no laxity; 2 = minimal laxity; 3 = moderate laxity; 4 = very lax. A negative change from Baseline indicates improvement." (NCT00618618)
Timeframe: Baseline and Week 4, Week 8, Week 12, Week 16 (4 weeks after last treatment) and Week 24 (12 weeks after last treatment)

,,,
Interventionunits on a scale (Mean)
Week 4Week 8Week 12Week 16Week 24
Deoxycholic Acid Injection 0.2 mL/0.7 cm-0.1-0.2-0.1-0.2-0.2
Deoxycholic Acid Injection 0.2 mL/1.0 cm-0.10.1-0.2-0.3-0.4
Deoxycholic Acid Injection 0.4 mL/1.0 cm-0.2-0.1-0.2-0.2-0.1
Pooled Placebo0.0-0.1-0.1-0.1-0.2

[back to top]

Change From Baseline to Each Visit in Submental Fat (SMF) Rating Scale Score

"The SMF rating scale score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~A negative change from Baseline indicates improvement." (NCT00618618)
Timeframe: Baseline and Week 4, Week 8, Week 12, Week 16 (4 weeks after last treatment) and Week 24 (12 weeks after last treatment)

,,,
Interventionunits on a scale (Mean)
Week 4Week 8Week 12Week 16Week 24
Deoxycholic Acid Injection 0.2 mL/0.7 cm-0.3-0.6-0.9-1.0-1.0
Deoxycholic Acid Injection 0.2 mL/1.0 cm-0.5-0.6-1.0-1.2-1.2
Deoxycholic Acid Injection 0.4 mL/1.0 cm-0.1-0.5-0.7-0.8-1.0
Pooled Placebo-0.3-0.4-0.4-0.4-0.4

[back to top]

Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Weight, Vital Signs, and Physical Examinations

(NCT00618722)
Timeframe: From the first dose of study drug until 12 weeks after the last dose (up to 24 weeks after first treatment).

,,,
Interventionparticipants (Number)
Laboratory ValuesWeightVital SignsPhysical Examinations
Deoxycholic Acid Injection 1 mg/cm²0000
Deoxycholic Acid Injection 2 mg/cm²0000
Deoxycholic Acid Injection 4 mg/cm²1000
Placebo0000

[back to top]

Percentage of Participants With a Response in the Subject Global Improvement Rating

"Participants were asked to rate their total improvement or worsening in the appearance and physical feeling of their chin and neck area since before they received study treatment, whether or not they believed it was due to study treatment or to any other cause.~0 = Very much worse, 1 = Much worse, 2 = Minimally worse, 3 = No change, 4 = Minimally improved, 5 = Much improved, 6 = Very much improved.~Response is defined as any improvement, ie, a global improvement rating of 4, 5, or 6." (NCT00618722)
Timeframe: 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²88.9
Deoxycholic Acid Injection 2 mg/cm²78.9
Deoxycholic Acid Injection 4 mg/cm²94.7
Placebo50.0

[back to top]

Change From Baseline in the Cervicomental Angle

The cervicomental angle was measured using a profile view photograph obtained at each visit. A goniometer was used to determine the angle. Cervicomental angle measurements less than 80 degrees are excluded, due to error in measurement. (NCT00618722)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventiondegrees (Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.7
Deoxycholic Acid Injection 2 mg/cm²2.3
Deoxycholic Acid Injection 4 mg/cm²6.9
Placebo-2.3

[back to top]

Change From Baseline in Submental Fat (SMF) Rating Scale Score

"The SMF rating scale score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~A negative change from Baseline indicates improvement." (NCT00618722)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.9
Deoxycholic Acid Injection 2 mg/cm²-0.8
Deoxycholic Acid Injection 4 mg/cm²-0.7
Placebo-0.5

[back to top]

Change From Baseline in Subject Satisfaction With Appearance Rating Scale

The Subject Satisfaction with Appearance Rating Scale assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement. (NCT00618722)
Timeframe: Baseline and 4 weeks after last treatment (up to 16 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²3.8
Deoxycholic Acid Injection 2 mg/cm²3.3
Deoxycholic Acid Injection 4 mg/cm²3.5
Placebo1.9

[back to top]

Number of Participants With Adverse Events

"The investigator determined the relationship of each adverse event to the administration of study drug.~Severity of adverse events was determined using the following scale:~Mild: The participant is aware of a sign or symptom, but it is easily tolerated~Moderate: Discomfort or interference with usual activity~Severe: Incapacitating, with inability to engage in usual activity.~A serious AE (SAE) was defined as an event that may constitute a significant medical hazard or side-effect, regardless of the investigator or sponsor's opinion regarding relatedness to study material. Serious events included, but were not limited to, any event that:~was fatal~was life-threatening~required inpatient hospitalization or prolongation of existing hospitalization~resulted in persistent or significant disability/incapacity~was a congenital anomaly/birth defect~other significant medical hazard" (NCT00618722)
Timeframe: From the first dose of study drug until 12 weeks after the last dose (up to 24 weeks after first treatment).

,,,
Interventionparticipants (Number)
Any adverse eventAdverse event associated with treatment areaStudy drug-related adverse eventSevere adverse eventStudy drug-related severe adverse eventSerious adverse eventDiscontinued due to adverse eventDeaths
Deoxycholic Acid Injection 1 mg/cm²20202000000
Deoxycholic Acid Injection 2 mg/cm²19191931000
Deoxycholic Acid Injection 4 mg/cm²22212132000
Placebo21202010000

[back to top]

Change From Baseline in Skin Laxity Rating

"Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale:~1 = no laxity; 2 = minimal laxity; 3 = moderate laxity; 4 = very lax. A negative change from Baseline indicates improvement." (NCT00618722)
Timeframe: Baseline and Week 4, Week 8, Week 12, Week 16 (4 weeks after last treatment) and Week 24 (12 weeks after last treatment)

,,,
Interventionunits on a scale (Least Squares Mean)
Week 4Week 8Week 12Week 16Week 24
Deoxycholic Acid Injection 1 mg/cm²0.10.10.10.10.1
Deoxycholic Acid Injection 2 mg/cm²-0.1-0.10.1-0.2-0.3
Deoxycholic Acid Injection 4 mg/cm²0.00.10.00.00.0
Placebo-0.2-0.1-0.30.0-0.1

[back to top]

Fungal-free Survival at End of Study Drug Therapy in Infants With End-organ Dissemination

Fungal-free survival was assessed by an independent data review panel (DRP). Fungal-free survival is defined as the percentage of participants alive at the end of study drug therapy with a mycological response of eradication based upon the DRP assessment and no requirement for alternative systemic antifungal therapy for continued treatment. (NCT00815516)
Timeframe: The end of study drug therapy; maximum of 42 days

Interventionpercentage of participants (Number)
Micafungin42.9
Amphotericin B33.3

[back to top]

Fungal-free Survival One Week After Last Dose of Study Drug in Infants With End-organ Dissemination

Fungal-free survival was assessed by an independent data review panel (DRP). Fungal-free survival is defined as the percentage of participants alive one week after last dose of study drug with a mycological response of eradication based upon the DRP assessment and no requirement for alternative systemic antifungal therapy for continued treatment. (NCT00815516)
Timeframe: One week after the last dose of study drug (maximum of 49 days)

Interventionpercentage of participants (Number)
Micafungin42.9
Amphotericin B33.3

[back to top]

Follow-up Status for Infants With End-organ Assessments

"End-organ dissemination was assessed through abdominal ultrasound and/or computed tomography (CT), echocardiogram, head imaging and retinal exam. Each specific finding, documented by 1 of these techniques, was evaluated as follows:~Improvement: Improvement in size, number or density of identified lesions. Complete response was not expected but may have been documented.~Stabilization: Minor improvement or no change in size, number or density of identified lesions.~Worsening: Increase in size or number of identified lesions." (NCT00815516)
Timeframe: Baseline and 30 days after the last dose of study drug (maximum of 72 days)

,
Interventionpercentage of participants (Number)
ImprovedStableWorsenedNot Assessed
Amphotericin B33.3066.70
Micafungin57.114.314.314.3

[back to top]

Percentage of Participants With Recurrent Fungal Infections

A recurrent infection is defined as a systemic fungal infection in an infant with eradication at the end of study drug therapy, who developed positive blood cultures or a mycologically confirmed deep-seated Candida infection, with the same species as the enrolling infection. (NCT00815516)
Timeframe: Up to 30 days after the last dose of study drug (maximum of 72 days)

Interventionpercentage of participants (Number)
Micafungin0
Amphotericin B12.5

[back to top]

Time to Mycological Clearance of Invasive Candidiasis

"Time to mycological clearance of invasive candidiasis is defined as the time from first dose to the day of mycological eradication for baseline invasive candidiasis infection.~Eradication was defined as a culture or histologically documented absence of the infecting Candida species from all positive normally sterile sites during therapy, documented by 2 negative samples, drawn at least 24 hours apart, or for for Candida meningitis and/or candiduria, 1 negative culture.~Infants without eradication during the treatment period and who survived were censored at one day after the end of treatment. Infants without eradication who died before completing the treatment period or were lost to follow-up during the treatment were censored at their death or last contact day." (NCT00815516)
Timeframe: From first dose up to 30 days after the last dose of study drug (maximum of 72 days)

Interventiondays (Median)
Micafungin6.0
Amphotericin B3.0

[back to top]

Time to Positive Clinical Response

"Time to a positive clinical response is defined as the time from the first dose to the day during the treatment period that a positive clinical response (defined as a complete response or partial response) is observed for the first time, assessed by the Investigator.~Complete Response is defined as the resolution of all attributable signs related to fungal infection, if present at baseline and Partial Response is defined as improvement in attributable signs related to the fungal infection, if present at baseline.~Infants without positive responses and who survived were censored at one day post the end of treatment. Infants without positive responses who died before completing the treatment period, or were lost to follow-up during the treatment were censored at their death or last contact day." (NCT00815516)
Timeframe: From first dose up to 30 days after the last dose of study drug (maximum of 72 days)

Interventiondays (Median)
Micafungin8.0
Amphotericin B11.0

[back to top]

Clinical Response at the End of Study Drug Therapy

"Clinical response assessments were based on the following definitions and assessed by the DRP:~Complete Response: Resolution of all attributable signs related to fungal infection, if present at baseline.~Partial Response: Improvement in attributable signs related to the fungal infection, if present at baseline.~Stabilization: Minor improvement or no change in attributable signs related to the fungal infection, if present at baseline, and infant continued on therapy without deterioration.~Progression: Deterioration in attributable signs related to the fungal infection, if present at baseline; or if death occurred presumably related to a fungal infection." (NCT00815516)
Timeframe: Baseline and end of study drug therapy; maximum of 42 days

,
Interventionpercentage of participants (Number)
CompletePartialStableProgressionMissing
Amphotericin B70.0010.020.00
Micafungin55.65.65.616.716.7

[back to top]

Clinical Response One Week After Last Dose of Study Drug

"Clinical response assessments were based on the following definitions and assessed by the DRP:~Complete Response: Resolution of all attributable signs related to fungal infection, if present at baseline.~Partial Response: Improvement in attributable signs related to the fungal infection, if present at baseline.~Stabilization: Minor improvement or no change in attributable signs related to the fungal infection, if present at baseline, and infant continued on therapy without deterioration.~Progression: Deterioration in attributable signs related to the fungal infection, if present at baseline; or if death occurred presumably related to a fungal infection." (NCT00815516)
Timeframe: Baseline and one week after the last dose of study drug (maximum of 49 days)

,
Interventionpercentage of participants (Number)
CompletePartialStableProgressionMissing
Amphotericin B70.0010.020.00
Micafungin55.65.65.65.627.8

[back to top]

Percentage of Participants With Emergent Fungal Infections

"An emergent fungal infection is defined as~An invasive fungal infection which is detected at any time during the study that is a non-Candida organism, or~An invasive fungal infection which is detected during the treatment or post-treatment period with a Candida species identified other than those detected at Baseline. If this occurred within 96 hours of the first dose of study drug, the infection was considered part of the final diagnosis of enrolling infection and not an emergent infection." (NCT00815516)
Timeframe: Up to 30 days after the last dose of study drug (maximum of 72 days)

Interventionpercentage of participants (Number)
Micafungin5.0
Amphotericin B0

[back to top]

Mycological Response at End of Study Drug Therapy

"Mycological response assessments were based on the following definitions and assessed by the DRP:~Eradication: Culture or histologically documented absence of the infecting Candida species from all positive normally sterile sites during therapy, documented by 2 negative samples, drawn at least 24 h apart; for Candida meningitis and/or candiduria, 1 negative culture.~Persistence: Continued isolation or histological documentation from a normally sterile site." (NCT00815516)
Timeframe: End of study drug therapy; maximum of 42 days

,
Interventionpercentage of participants (Number)
EradicationPersistenceNot Assessed
Amphotericin B80.020.00
Micafungin55.010.035.0

[back to top]

Mycological Response One Week After Last Dose of Study Drug

"Mycological response assessments were based on the following definitions and assessed by the DRP:~Eradication: Culture or histologically documented absence of the infecting Candida species from all positive normally sterile sites during therapy, documented by 2 negative samples, drawn at least 24 h apart; for Candida meningitis and/or candiduria, 1 negative culture.~Persistence: Continued isolation or histological documentation from a normally sterile site." (NCT00815516)
Timeframe: One week after the last dose of study drug (maximum of 49 days)

,
Interventionpercentage of participants (Number)
Continuing Eradication/EradicationPersistenceNot Assessed
Amphotericin B80.020.00
Micafungin55.010.035.0

[back to top]

Plasma Micafungin Concentration

(NCT00815516)
Timeframe: 15 minutes post intravenous infusion (IV), 4-8 hours post IV and 15-24 hours post IV

Interventionng/mL (Mean)
Within 15 Minutes Post IV4-8 Hours Post IV15-24 Hours Post IV
Micafungin25130.523751.714118.3

[back to top]

Fungal-free Survival

"Fungal-free survival was assessed by an independent data review panel (DRP). Fungal-free survival is defined as the percentage of participants alive at one week following the last dose of study drug with a mycological response of eradication and no requirement for alternative systemic antifungal therapy for continued treatment.~Eradication was defined as culture or histologically documented absence of the infecting Candida species from all positive normally sterile sites during therapy, documented by 2 negative samples, drawn at least 24 hours apart, or for Candida meningitis and/or candiduria, 1 negative culture." (NCT00815516)
Timeframe: One week after the last dose of study drug (maximum of 49 days)

Interventionpercentage of participants (Number)
Micafungin60.0
Amphotericin B70.0

[back to top]

Kaplan Meier (KM) Proportion of Participant Mortality

Kaplan Meier Proportion of participants who died over study with 90% Confidence Intervals. (NCT00885703)
Timeframe: Measured from study entry through Week 24

Interventionproportion of participants (Number)
Fluconazole 1200mg0.41
Fluconazole 1600mg0.30
Fluconazole 2000mg0.36
Ampho B0.24

[back to top]

Length of Hospitalization

Duration of first hospitalization in days starting at entry in safety population. (NCT00885703)
Timeframe: Measured from study entry through Week 10

InterventionDays (Median)
Fluconazole 1200mg15
Fluconazole 1600mg17.5
Fluconazole 2000mg18
Ampho B18.5

[back to top]

Number of Participants With CNS IRIS

Number of participants who were diagnosed with CNS immune reconstitution inflammatory syndrome (IRIS) (NCT00885703)
Timeframe: Measured from study entry through Week 24

InterventionParticipants (Count of Participants)
Fluconazole 1200mg1
Fluconazole 1600mg0
Fluconazole 2000mg0
Ampho B1

[back to top]

Number of Participants With Progression of Symptoms

"Progression of symptoms is defined as:~Died (including early deaths)~Discontinued Fluconazole and started ampho B~Had a positive cryptococcal culture at week 10~Microbiological Failure (i.e., relapse of CM)~Complication of CM (e.g., obstructive hydrocephalus or vascular complications such as venous or arterial thrombosis)~CM IRIS causing increased inflammation after ART exposure~New CNS Ol (e.g., toxoplasmosis, PML, CNS lymphoma)~Possibly related to CM but mechanism indeterminate~Other defined complication unrelated to CM" (NCT00885703)
Timeframe: Measured from study entry through Week 24

InterventionParticipants (Count of Participants)
Fluconazole 1200mg14
Fluconazole 1600mg21
Fluconazole 2000mg24
Ampho B19

[back to top]

Number of Participants With Grade 3 and 4 Adverse Events

"Occurrence of grade 3 (severe) and 4 (life-threatening) sign and symptoms events (as defined by FSTRF Appendix 29)~Occurrence of grade 3 (severe) and 4 (life-threatening) laboratory events (as defined by FSTRF Appendix 76)~See DAIDS AE Grading table V1.0" (NCT00885703)
Timeframe: Measured from study entry through Week 24

,,,
InterventionParticipants (Count of Participants)
Sign/Symptom EventsLaboratory Events
Ampho B2430
Fluconazole 1200mg1612
Fluconazole 1600mg2327
Fluconazole 2000mg3226

[back to top]

Results of Functional Status Evaluation

"Functional assessment of work status and ability. Consists of 2 measures: 1) Does participants have full time work status 2) Does participant have functional ability to work.~The measure from 6 week before enrollment will be referred to as 'baseline'." (NCT00885703)
Timeframe: Measured 6 weeks before enrollment, at study entry, at Week 10, and at Week 24

,,,
InterventionParticipants (Count of Participants)
Baseline Had full time work statusEntry Had full time work statusWeek 10 Had full time work statusWeek 24 Had full time work statusBaseline Had functional ability to workEntry Had functional ability to workWeek 10 Had functional ability to workWeek 24 Had functional ability to work
Ampho B42913223871524
Fluconazole 1200mg1833716147
Fluconazole 1600mg41916184181819
Fluconazole 2000mg368917323916

[back to top]

Categorized Quantitative Culture Results

Count of participants who were CM negative (had no cryptococcal growth), CM negative after switching treatment (switched from Fluconazole to Ampho B or vice versa and later became CM negative), CM positive, Died, Lost to follow-up. Note: CM positive means continued to have cryptococcal growth. (NCT00885703)
Timeframe: At entry, Week 2, and Week 10

InterventionParticipants (Count of Participants)
Week 072337496Week 072337498Week 072337499Week 072337497Week 272337496Week 272337497Week 272337498Week 272337499Week 1072337496Week 1072337497Week 1072337498Week 1072337499
CM Negative after switching treatmentDiedLost to Follow-upCM PositiveCM Negative
Fluconazole 1200mg20
Fluconazole 1600mg45
Fluconazole 2000mg43
Ampho B46
Fluconazole 1200mg0
Fluconazole 2000mg0
Ampho B0
Fluconazole 1600mg0
Fluconazole 1200mg12
Fluconazole 1600mg27
Fluconazole 2000mg27
Ampho B29
Fluconazole 1600mg12
Fluconazole 2000mg10
Ampho B13
Fluconazole 1200mg5
Fluconazole 1600mg6
Fluconazole 2000mg6
Ampho B4
Fluconazole 1200mg3
Fluconazole 1600mg4
Fluconazole 2000mg3
Ampho B2
Fluconazole 1200mg8
Fluconazole 1600mg24
Fluconazole 2000mg22
Ampho B37
Fluconazole 1200mg1
Fluconazole 2000mg5
Fluconazole 1600mg10
Fluconazole 2000mg12
Ampho B5
Fluconazole 1600mg3
Fluconazole 2000mg1
Ampho B1

[back to top]

Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B

"Discontinuation of study-provided high dose fluconazole at or by week 10 Discontinuation of study-provided ampho B at or by week 2~Discontinuation includes discontinuing for any reason, including progression of symptoms, death, etc." (NCT00885703)
Timeframe: Measured from study entry through Week10

InterventionParticipants (Count of Participants)
Stage 1, Fluconazole 1200mg14
Stage 1, Fluconazole 1600mg11
Stage 1, Fluconazole 2000mg11
Stage 1, Ampho B6
Stage 2, Fluconazole 1600mg12
Stage 2, Fluconazole 2000mg13
Stage 2, Ampho B6

[back to top]

Change in Log10 Quantitative CSF Culture Results

"Change in quantitative CSF (cerebrospinal fluid) cultures.~Note: No further CSF specimens are drawn following a negative culture. Thus, only week 2 CSF cultures are considered in this analysis." (NCT00885703)
Timeframe: Entry and Week 2

InterventionLog10 CFU/mL (Median)
Fluconazole 1200mg-1.51
Fluconazole 1600mg-2.51
Fluconazole 2000mg-1.78
Ampho B-2.81

[back to top]

Results of the Neurological Examination

Results from Glasgow Coma Score, which provides assessment of impairment of conscious level in response to defined stimuli. Min score of 0 and max score of 15 (no mental impairment). (NCT00885703)
Timeframe: Measured at study entry, Week 2, and Week 10

InterventionParticipants (Count of Participants)
Week 072337496Week 072337497Week 072337498Week 072337499Week 272337496Week 272337497Week 272337498Week 272337499Week 1072337497Week 1072337498Week 1072337496Week 1072337499
Score = 15Score < 15
Fluconazole 1200mg5
Fluconazole 1600mg5
Fluconazole 2000mg5
Ampho B1
Fluconazole 1200mg17
Fluconazole 1600mg45
Fluconazole 2000mg42
Ampho B47
Fluconazole 1200mg2
Fluconazole 1600mg4
Fluconazole 2000mg4
Ampho B5
Fluconazole 1200mg15
Fluconazole 1600mg38
Fluconazole 2000mg36
Ampho B38
Fluconazole 1200mg1
Fluconazole 1600mg1
Fluconazole 2000mg1
Ampho B0
Fluconazole 1200mg11
Fluconazole 1600mg33
Fluconazole 2000mg26
Ampho B34

[back to top]

Change From Baseline in Submental Fat Volume

Submental fat volume was measured by magnetic resonance imaging (MRI). (NCT01032889)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionmm³ (Least Squares Mean)
Deoxycholic Acid Injection 1 mg/cm²-614
Deoxycholic Acid Injection 2 mg/cm²-118
Placebo-8.1

[back to top]

Change From Baseline in Submental Fat Thickness

Submental fat thickness was measured by magnetic resonance imaging (MRI). (NCT01032889)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionmm (Least Squares Mean)
Deoxycholic Acid Injection 1 mg/cm²-1.8
Deoxycholic Acid Injection 2 mg/cm²-1.9
Placebo-0.3

[back to top]

Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. A negative change from Baseline indicates improvement." (NCT01032889)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionunits on a scale (Least Squares Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.9
Deoxycholic Acid Injection 2 mg/cm²-1.3
Placebo-0.7

[back to top]

Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement. (NCT01032889)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionunits on a scale (Least Squares Mean)
Deoxycholic Acid Injection 1 mg/cm²-3.5
Deoxycholic Acid Injection 2 mg/cm²-4.5
Placebo-2.1

[back to top]

Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores

The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement. (NCT01032889)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionunits on a scale (Least Squares Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.7
Deoxycholic Acid Injection 2 mg/cm²-0.8
Placebo-0.4

[back to top]

Change From Baseline in Submental Fat Thickness

Submental thickness was measured using caliper devices. (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionmm (Mean)
Deoxycholic Acid Injection 1 mg/cm²-3.6
Deoxycholic Acid Injection 2 mg/cm²-3.8
Placebo-2.5

[back to top]

Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response

"A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²58.3
Deoxycholic Acid Injection 2 mg/cm²62.3
Placebo34.5

[back to top]

Percentage of Participants With a CR-SMFRS 2-grade Response

"A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²9.2
Deoxycholic Acid Injection 2 mg/cm²9.0
Placebo0.9

[back to top]

Percentage of Participants With a Subject Self Rating Scale (SSRS) Response

"A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.~The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²68.3
Deoxycholic Acid Injection 2 mg/cm²64.8
Placebo29.3

[back to top]

Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you currently have under your chin? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

,,
Interventionpercentage of participants (Number)
ImprovedNo changeWorsened
Deoxycholic Acid Injection 1 mg/cm²64.931.53.6
Deoxycholic Acid Injection 2 mg/cm²67.330.91.8
Placebo44.148.07.8

[back to top]

Change From Baseline in Self-rating of Attractiveness

"Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:~How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are? Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.~A positive change from Baseline indicates improvement." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

,,
Interventionunits on a scale (Mean)
Overall AppearanceChin / NeckEyesNoseMouthEntire Face
Deoxycholic Acid Injection 1 mg/cm²0.61.90.30.40.10.4
Deoxycholic Acid Injection 2 mg/cm²0.62.10.30.40.30.6
Placebo0.30.90.30.50.10.4

[back to top]

Change From Baseline in SSRS Scores

"The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.~A positive change from Baseline indicates improvement." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²2.9
Deoxycholic Acid Injection 2 mg/cm²2.9
Placebo1.5

[back to top]

Change From Baseline in CR-SMFRS Score

"The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~A negative change from Baseline indicates improvement." (NCT01294644)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.7
Deoxycholic Acid Injection 2 mg/cm²-0.8
Placebo-0.4

[back to top]

Change From Baseline in Submental Fat Thickness

Submental thickness was measured using caliper devices. (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionmm (Mean)
Deoxycholic Acid Injection 1 mg/cm²-3.8
Deoxycholic Acid Injection 2 mg/cm²-4.2
Placebo-1.7

[back to top]

Change From Baseline in CR-SMFRS Scores

"The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~A negative change from Baseline indicates improvement." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²-0.7
Deoxycholic Acid Injection 2 mg/cm²-0.9
Placebo-0.2

[back to top]

Change From Baseline in SSRS Scores

"The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.~A positive change from Baseline indicates improvement." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection 1 mg/cm²2.4
Deoxycholic Acid Injection 2 mg/cm²2.8
Placebo1.4

[back to top]

Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response

"A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²59.2
Deoxycholic Acid Injection 2 mg/cm²65.3
Placebo23.0

[back to top]

Percentage of Participants With a CR-SMFRS 2-grade Response

"A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²9.2
Deoxycholic Acid Injection 2 mg/cm²17.4
Placebo1.6

[back to top]

Percentage of Participants With a Subject Self Rating Scale (SSRS) Response

"A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.~The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection 1 mg/cm²53.3
Deoxycholic Acid Injection 2 mg/cm²66.1
Placebo28.7

[back to top]

Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you currently have under your chin? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

,,
Interventionpercentage of participants (Number)
ImprovementNo ChangeWorsened
Deoxycholic Acid Injection 1 mg/cm²67.032.01.0
Deoxycholic Acid Injection 2 mg/cm²73.622.63.8
Placebo32.459.38.3

[back to top]

Change From Baseline in Self-rating of Attractiveness

"Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:~How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are? Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.~A positive change from Baseline indicates improvement." (NCT01305577)
Timeframe: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

,,
Interventionunits on a scale (Mean)
Overall AppearanceChin/NeckEyesNoseMouthEntire Face
Deoxycholic Acid Injection 1 mg/cm²0.91.80.80.30.40.8
Deoxycholic Acid Injection 2 mg/cm²0.51.90.10.00.20.3
Placebo0.30.50.30.20.30.0

[back to top]

Percentage of Participants Who Achieved a Composite 1-grade Response

"A composite 1-grade response is defined as at least a 1-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme).~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat)." (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionpercentage of participants (Number)
Month 3 after last treatment (n = 142)Month 12 after last treatment (n = 128)
Deoxycholic Acid 2 mg/cm²72.575.0

[back to top]

Percent Change From Baseline in Submental Fat Thickness

Submental fat thickness was measured using calipers. (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionpercent change (Mean)
Month 3 after last treatment (n = 144)Month 12 after last treatment (n = 131)
Deoxycholic Acid 2 mg/cm²-27.2-30.9

[back to top]

Number of Participants With Adverse Events (AEs)

"Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard.~The severity of each AE was defined as either:~Mild: The participant was aware of the sign or symptom, but it was easily tolerated.~Moderate: The sign or symptom caused discomfort and interfered with usual activity.~Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity.~The investigator determined the relationship of each AE to the study drug using the question: Is there a reasonable possibility that the event may have been caused by treatment with the study drug?" (NCT01426373)
Timeframe: Up to 12 months after last treatment (maximum of 18 months from first treatment)

Interventionparticipants (Number)
Any adverse eventSerious adverse eventSevere adverse eventAdverse event leading to withdrawal from treatmentAdverse event leading to study discontinuationAdverse event leading to deathAdverse event related to study drugSerious adverse event related to study drugAdverse event associated with the treatment area
Deoxycholic Acid 2 mg/cm²16071115611550158

[back to top]

Mean Change From Baseline in Subject Self Rating Scale (SSRS)

The SSRS assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 (0 = extremely dissatisfied, 1 = dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly satisfied, 5 = satisfied and 6 = extremely satisfied). A positive change from baseline indicates improvement. (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionunits on a scale (Mean)
Month 3 after last treatment (n = 144)Month 12 after last treatment (n = 128)
Deoxycholic Acid 2 mg/cm²3.63.8

[back to top]

Mean Change From Baseline in Self-rating of Attractiveness

"Self-rating of Attractiveness assesses aspects of appearance from the participant's perspective with a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are? Each question was answered on a scale from 1 to 9 (1 = not at all attractive, 5 = neither attractive nor unattractive, and 9 = extremely attractive). A positive change from baseline indicates improvement." (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionunits on a scale (Mean)
Overall appearance - month 3 after last treatmentOverall appearance - month 12 after last treatmentChin/neck - month 3 after last treatmentChin/neck - month 12 after last treatmentEyes - month 3 after last treatmentEyes - month 12 after last treatmentNose - month 3 after last treatmentNose - month 12 after last treatmentMouth - month 3 after last treatmentMouth - month 12 after last treatmentEntire face - month 3 after last treatmentEntire face - month 12 after last treatment
Deoxycholic Acid 2 mg/cm²0.81.02.63.10.40.60.30.60.30.60.50.8

[back to top]

Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). A negative change from baseline indicates improvement." (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionunits on a scale (Mean)
Month 3 after last treatment (n = 142)Month 12 after last treatment (n = 127)
Deoxycholic Acid 2 mg/cm²-1.2-1.3

[back to top]

Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from baseline indicates improvement. (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionunits on a scale (Mean)
Month 3 after last treatment (n = 145)Month 12 after last treatment (n = 129)
Deoxycholic Acid 2 mg/cm²-4.3-4.2

[back to top]

Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)

The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). A negative change from baseline indicates improvement. (NCT01426373)
Timeframe: Baseline and months 3, 6, 9, and 12 after last treatment

Interventionunits on a scale (Mean)
Month 3 after last treatment (n = 144)Month 6 after last treatment (n = 133)Month 9 after last treatment (n = 134)Month 12 after last treatment (n = 131)
Deoxycholic Acid 2 mg/cm²-1.3-1.3-1.4-1.4

[back to top]

Response to Subject Global Questions

"Participants answered 3 questions on a 7-point scale that ranged from a great deal worse to a great deal better (questions 1 and 2) or from extremely dissatisfied to extremely satisfied (question 3).~Question 1: Since the start of the study, how would you rate the fat under your chin right now?~Question 2: Since the start of the study, how would you rate the definition between your chin and neck right now?~Question 3: How satisfied are you with the treatment you received in this study?" (NCT01426373)
Timeframe: Month 3 and month 12 after last treatment

,
Interventionparticipants (Number)
Question 1 - a great deal worseQuestion 1 - moderately worseQuestion 1 - a little worseQuestion 1 - about the sameQuestion 1 - a little betterQuestion 1 - moderately betterQuestion 1 - a great deal betterQuestion 2 - a great deal worseQuestion 2 - moderately worseQuestion 2 - a little worseQuestion 2 - about the sameQuestion 2 - a little betterQuestion 2 - moderately betterQuestion 2 - a great deal betterQuestion 3 - extremely dissatisfiedQuestion 3 - moderately dissatisfiedQuestion 3 - a little dissatisfiedQuestion 3 - neither dissatisfied nor satisfiedQuestion 3 - a little satisfiedQuestion 3 - moderately satisfiedQuestion 3 - extremely satisfied
Month 12 After Last Treatment011723326601052738591126113079
Month 3 After Last Treatment010622486800052753601025154379

[back to top]

Percentage of Participants Who Achieved a Composite 2-grade Response

"A composite 2-grade response is defined as at least a 2-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme).~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat)." (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionpercentage of participants (Number)
Month 3 after last treatment (n = 142)Month 12 after last treatment (n = 128)
Deoxycholic Acid 2 mg/cm²14.120.3

[back to top]

Change From Baseline in Line Drawing Assessment

Each participant was given 2 example line drawings representing each of the 5 submental fat grades (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme) and asked to select the drawing that best represents their current profile. Improvement is any decrease in grade, and worsening is any increase in grade. (NCT01426373)
Timeframe: Baseline and month 3 after last treatment

Interventionparticipants (Number)
Improved by > 2Improved by 2Improved by 1UnchangedWorsened by 1Worsened by 2Worsened by > 2
Deoxycholic Acid 2 mg/cm²27522531800

[back to top]

Change From Baseline in Submental Skin Laxity Grade (SMSLG)

"SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).~Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds));~Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging);~Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging);~Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging)." (NCT01426373)
Timeframe: Baseline and month 3 and month 12 after last treatment

Interventionunits on a scale (Mean)
Month 3 after last treatment (n = 144)Month 12 after last treatment (n = 131)
Deoxycholic Acid 2 mg/cm²-0.3-0.3

[back to top]

Percentage of Participants With a Magnetic Resonance Imaging (MRI) Response

An MRI responder is a participant who exhibited at least a 10% reduction in submental fat volume as measured by MRI from Baseline to 12 weeks after last treatment. Magnetic resonance imaging was evaluated in a subset of participants at selected centers. (NCT01542034)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection46.3
Placebo5.3

[back to top]

Percentage of Participants Who Achieved a Composite 1-grade Response

"A composite 1-grade response is defined as at least a 1-grade improvement from Baseline on both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat." (NCT01542034)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection70.0
Placebo18.6

[back to top]

Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement. (NCT01542034)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection-3.56
Placebo-1.16

[back to top]

Percentage of Participants Who Achieved a Composite 2-grade Response

"A composite 2-grade response is defined as at least a 2-grade improvement from Baseline on both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat." (NCT01542034)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection13.4
Placebo0.0

[back to top]

Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement. (NCT01546142)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionunits on a scale (Mean)
Deoxycholic Acid Injection-3.48
Placebo-1.42

[back to top]

Percentage of Participants With a Magnetic Resonance Imaging (MRI) Response

An MRI responder is a participant who exhibited at least a 10% reduction in submental fat volume as measured by MRI from Baseline to 12 weeks after last treatment. Magnetic resonance imaging was evaluated in a subset of participants at selected centers. (NCT01546142)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection40.2
Placebo5.2

[back to top]

Percentage of Participants Who Achieved a Composite 2-grade Response

"A composite 2-grade response is defined as at least a 2-grade improvement from Baseline on both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat." (NCT01546142)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection18.6
Placebo3.0

[back to top]

Percentage of Participants Who Achieved a Composite 1-grade Response

"A composite 1-grade response is defined as at least a 1-grade improvement from Baseline on both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) 12 weeks after the last treatment.~The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.~The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat." (NCT01546142)
Timeframe: Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)

Interventionpercentage of participants (Number)
Deoxycholic Acid Injection66.5
Placebo22.2

[back to top]

Number of Participants With an Adverse Event (AE)

An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, is also an AE. (NCT01945281)
Timeframe: 8 weeks after end of study therapy (up to 146 days)

InterventionParticipants (Count of Participants)
Caspofungin28
Amphotericin B Deoxycholate16

[back to top]

Percentage of Participants With Fungal-free Survival Through the 2-week Post-therapy Period

Fungal-free survival is those participants who survived up to 2 weeks post-therapy, and had documented microbiological eradication of Candida species (sp.) from follow-up cultures collected after the initiation of study therapy. Microbiological eradication denotes negative follow-up cultures for Candida sp. from the site of infection. If a culture is not obtained on the day of assessment, the last culture after study entry may be used to assist in the assessment of microbiological eradication. If the last culture is negative for Candida sp., then microbiological eradication would be considered achieved. (NCT01945281)
Timeframe: Up to 104 days

InterventionPercentage of Participants (Number)
Caspofungin71.0
Amphotericin B Deoxycholate68.8

[back to top]

Percentage of Participants With Fungal-free Survival Through the End of Study Treatment

Fungal-free survival is those participants who survived up to end of study treatment, and had documented microbiological eradication of Candida sp. from follow-up cultures collected after the initiation of study therapy. Microbiological eradication denotes negative follow-up cultures for Candida sp. from the site of infection. If a culture is not obtained on the day of assessment, the last culture after study entry may be used to assist in the assessment of microbiological eradication. If the last culture is negative for Candida sp., then microbiological eradication would be considered achieved. (NCT01945281)
Timeframe: Up to 90 days

InterventionPercentage of Participants (Number)
Caspofungin71.0
Amphotericin B Deoxycholate75.0

[back to top]

Change From Baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement. (NCT02007434)
Timeframe: Baseline and Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection-0.6
Paradigm 1 / Placebo-0.7
Paradigm 2 / Deoxycholic Acid Injection-0.6
Paradigm 2 / Placebo-0.8
Paradigm 3 / Deoxycholic Acid Injection-0.4
Paradigm 3 / Placebo0.0
Paradigm 4 / Deoxycholic Acid Injection-0.4
Paradigm 4 / Placebo-0.3

[back to top]

Change From Baseline in Pain Visual Analog Scale Scores

Participants were provided with a scale 100 mm in length and were asked to mark the place on the line that best represents his or her pain associated with the area treated with study drug. The scale ranged from 0 (no pain) to 100 (most severe pain possible). (NCT02007434)
Timeframe: Baseline and Day 84

Interventionunits on a scale (Median)
Paradigm 1 / Deoxycholic Acid Injection0.0
Paradigm 1 / Placebo0.0
Paradigm 2 / Deoxycholic Acid Injection0.0
Paradigm 2 / Placebo0.0
Paradigm 3 / Deoxycholic Acid Injection0.0
Paradigm 3 / Placebo0.0
Paradigm 4 / Deoxycholic Acid Injection0.0
Paradigm 4 / Placebo0.0

[back to top]

Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. A negative change from Baseline indicates improvement." (NCT02007434)
Timeframe: Baseline and Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection-1.2
Paradigm 1 / Placebo-0.7
Paradigm 2 / Deoxycholic Acid Injection-0.9
Paradigm 2 / Placebo-0.5
Paradigm 3 / Deoxycholic Acid Injection-0.8
Paradigm 3 / Placebo-0.8
Paradigm 4 / Deoxycholic Acid Injection-0.7
Paradigm 4 / Placebo-0.5

[back to top]

Change From Baseline in Subject Self Rating Scale (SSRS)

The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement. (NCT02007434)
Timeframe: Baseline and Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection2.8
Paradigm 1 / Placebo2.3
Paradigm 2 / Deoxycholic Acid Injection3.2
Paradigm 2 / Placebo1.8
Paradigm 3 / Deoxycholic Acid Injection2.3
Paradigm 3 / Placebo2.3
Paradigm 4 / Deoxycholic Acid Injection2.4
Paradigm 4 / Placebo2.0

[back to top]

Change From Baseline in Submental Skin Laxity Grades (SMSLG)

Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale: 1 = no laxity; 2 = mild laxity; 3 = moderate laxity; 4 = severe laxity. A negative change from Baseline indicates improvement. (NCT02007434)
Timeframe: Baseline and Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection0.2
Paradigm 1 / Placebo0.0
Paradigm 2 / Deoxycholic Acid Injection0.1
Paradigm 2 / Placebo0.5
Paradigm 3 / Deoxycholic Acid Injection0.3
Paradigm 3 / Placebo0.5
Paradigm 4 / Deoxycholic Acid Injection0.3
Paradigm 4 / Placebo0.3

[back to top]

Bruising Grading Scale Scores

"The following grading system was used for the assessment of bruising:~Bruising absent (0)~Bruising associated with 1 to 3 needle insertion points (1)~Bruising spreading beyond 4 or more individual needle insertion points but contained within the treatment area (2)~Bruising covering the entire treatment area but contained within the treatment area (3)~Bruising of the neck and face beyond the treatment area (4)" (NCT02007434)
Timeframe: Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection0.0
Paradigm 1 / Placebo0.0
Paradigm 2 / Deoxycholic Acid Injection0.0
Paradigm 2 / Placebo0.0
Paradigm 3 / Deoxycholic Acid Injection0.0
Paradigm 3 / Placebo0.0
Paradigm 4 / Deoxycholic Acid Injection0.0
Paradigm 4 / Placebo0.0

[back to top]

Swelling Grading Scale Scores

"The following grading system was used for the assessment of swelling:~Swelling/edema absent (0)~Minimal swelling/edema contained within treatment area (1)~Modest swelling/edema contained within treatment area (2)~Substantial swelling/edema contained within treatment area (3)~Swelling/edema of the neck and face beyond the treatment area (4)" (NCT02007434)
Timeframe: Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection0.0
Paradigm 1 / Placebo0.0
Paradigm 2 / Deoxycholic Acid Injection0.0
Paradigm 2 / Placebo0.0
Paradigm 3 / Deoxycholic Acid Injection0.0
Paradigm 3 / Placebo0.0
Paradigm 4 / Deoxycholic Acid Injection0.0
Paradigm 4 / Placebo0.0

[back to top]

Change From Baseline in Pain Assessment Using McGill Pain Questionnaire

Participants rated 15 pain characteristics by using a number to signify how much of that specific type of pain they were experiencing using the Short-Form McGill Pain Questionnaire. The pain characteristic options included Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, and Punishing- cruel. Participants assessed the intensity of each characteristic using the following score system: none (0), mild (1), moderate (2), and severe (3). In addition, present pain was assessed on a scale from 0 (no pain) to 5 (excruciating). (NCT02007434)
Timeframe: Baseline (predose) and Day 84

,,,,,,,
Interventionunits on a scale (Mean)
ThrobbingShootingStabbingSharpCrampingGnawingHot-BurningAchingHeavyTenderSplittingTiring-ExhaustingSickeningFearfulPunishing-CruelPresent pain
Paradigm 1 / Deoxycholic Acid Injection0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Paradigm 1 / Placebo0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Paradigm 2 / Deoxycholic Acid Injection0.00.00.00.00.00.00.00.00.00.10.00.00.00.00.00.0
Paradigm 2 / Placebo0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Paradigm 3 / Deoxycholic Acid Injection0.00.00.00.00.00.00.00.10.10.10.00.00.00.00.00.0
Paradigm 3 / Placebo0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Paradigm 4 / Deoxycholic Acid Injection0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Paradigm 4 / Placebo0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

[back to top]

Patient Experience Questions

"Participants were asked to complete 3 patient experience questions, each answered as Yes or No:~Given your experience in this study:~Would you recommend this procedure to a friend?~Would you agree to receive additional treatments?~Has the treatment you received in this study affected your normal activities?~The percentage of participants answering Yes on each question is reported." (NCT02007434)
Timeframe: Day 84

,,,,,,,
Interventionpercentage of participants (Number)
Recommend to a FriendReceive Additional TreatmentsNormal Activity Affected
Paradigm 1 / Deoxycholic Acid Injection818113
Paradigm 1 / Placebo33670
Paradigm 2 / Deoxycholic Acid Injection818813
Paradigm 2 / Placebo50500
Paradigm 3 / Deoxycholic Acid Injection949419
Paradigm 3 / Placebo1001000
Paradigm 4 / Deoxycholic Acid Injection727811
Paradigm 4 / Placebo7510025

[back to top]

Change From Baseline in Submental Fat Thickness

Submental thickness was measured using caliper devices. (NCT02007434)
Timeframe: Baseline and Day 84

Interventionmm (Mean)
Paradigm 1 / Deoxycholic Acid Injection-1.4
Paradigm 1 / Placebo-2.3
Paradigm 2 / Deoxycholic Acid Injection-1.6
Paradigm 2 / Placebo-0.3
Paradigm 3 / Deoxycholic Acid Injection-0.9
Paradigm 3 / Placebo-2.3
Paradigm 4 / Deoxycholic Acid Injection-1.5
Paradigm 4 / Placebo-2.8

[back to top]

Induration Grading Scale Scores

"The following grading system was used for the assessment of induration:~Induration absent to minimal (0)~Induration associated with at least approximately 30% of the treatment area (1)~Induration associated with greater than approximately 30% to at least 60% of the treatment area (2)~Induration covering the entire treatment area but contained within the treatment area (3)~Induration of the neck and face beyond the treatment area (4)" (NCT02007434)
Timeframe: Day 84

Interventionunits on a scale (Mean)
Paradigm 1 / Deoxycholic Acid Injection0.0
Paradigm 1 / Placebo0.0
Paradigm 2 / Deoxycholic Acid Injection0.1
Paradigm 2 / Placebo0.0
Paradigm 3 / Deoxycholic Acid Injection0.0
Paradigm 3 / Placebo0.0
Paradigm 4 / Deoxycholic Acid Injection0.1
Paradigm 4 / Placebo0.0

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).~The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst)." (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 442.9
Placebo Injection - Grade 40

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 460.7
Placebo Injection - Grade 420.0

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 471.4
Placebo Injection - Grade 413.3

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 174.2
Placebo Injection - Grade 120.0
ATX-101 (Deoxycholic Acid) Injection - Grade 496.4
Placebo Injection - Grade 426.7

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 167.7
Placebo Injection - Grade 133.3
ATX-101 (Deoxycholic Acid) Injection - Grade 489.3
Placebo Injection - Grade 446.7

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).~The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst)." (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection - Grade 161.3
Placebo Injection - Grade 16.7
ATX-101 (Deoxycholic Acid) Injection - Grade 489.3
Placebo Injection - Grade 413.3

[back to top]

Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)

The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy. (NCT02035267)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionscores on a scale (Mean)
ATX-101 (Deoxycholic Acid) Injection - Grade 1-0.3
Placebo Injection - Grade 1-0.1
ATX-101 (Deoxycholic Acid) Injection - Grade 4-0.3
Placebo Injection - Grade 4-0.2

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection84.0
Placebo41.7

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection80.0
Placebo45.8

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).~The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst)." (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection8.0
Placebo4.2

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection20.0
Placebo20.8

[back to top]

Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)

The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy. (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionscores on a scale (Mean)
ATX-101 (Deoxycholic Acid) Injection-0.5
Placebo-0.1

[back to top]

Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).~The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst)." (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection68.0
Placebo25.0

[back to top]

Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). (NCT02123134)
Timeframe: Baseline and up to Week 32 (12 weeks after last treatment)

Interventionpercentage of participants (Number)
ATX-101 (Deoxycholic Acid) Injection60.0
Placebo12.5

[back to top]

Change From Baseline in the Submental Skin Laxity Scale (SMSLG)

"SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).~Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy [no skin draping or skin sagging]; Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy [slight skin draping and sagging]; Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy [moderate skin draping and skin sagging]; Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy [marked skin draping and sagging]. A negative change from Baseline indicates improvement." (NCT02438813)
Timeframe: Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)

,,,,,
Interventionscore on a scale (Mean)
BaselineChange to Follow-up VisitChange to EOT Visit
Deoxycholic Acid (ATX-101)2.0-0.1-0.2
Energy Devices2.1-0.4-0.3
Laser Liposuction2.0-0.4-0.5
Not Elected Treatment2.0-0.2-0.3
Other Treatments2.0-0.4-0.2
Surgical2.2-0.6-0.6

[back to top]

Change From Baseline in the Subject Self Rating Scale (SSRS)

"The participant was asked to answer the question: Considering your appearance in association with your face and chin, how satisfied do you feel with your appearance at the present time? using a 7-point scale: 0=Extremely dissatisfied, 1=Dissatisfied, 2=Slightly dissatisfied, 3=neither satisfied nor dissatisfied, 4=Slightly satisfied, 5=Satisfied, and 6=Extremely satisfied. A positive change from Baseline indicates improvement." (NCT02438813)
Timeframe: Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)

,,,,,
Interventionscore on a scale (Mean)
BaselineChange to Follow-up VisitChange to EOT
Deoxycholic Acid (ATX-101)2.31.02.0
Energy Devices2.11.62.1
Laser Liposuction1.43.64.5
Not Elected Treatment2.21.12.1
Other Treatments2.61.21.3
Surgical2.02.42.8

[back to top]

Change From Baseline in the Patient-Reported Submental Fat Impact Scale (PR-SMFIS)

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics related to the appearance of submental fullness (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from Baseline indicates improvement. (NCT02438813)
Timeframe: Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)

,,,,,
Interventionscore on a scale (Mean)
BaselineChange to Follow-up VisitChange to EOT Visit
Deoxycholic Acid (ATX-101)6.9-1.2-2.8
Energy Devices6.2-1.8-2.4
Laser Liposuction9.0-6.6-6.5
Not Elected Treatment6.9-1.5-2.9
Other Treatments7.0-2.4-2.3
Surgical7.9-4.6-5.4

[back to top]

Change From Baseline in the Patient Self-Perception of Age (SPA)

The participant rated their facial age in years at Baseline and at the End of Treatment Visit by answering the question: How many years difference compare to your actual age? A negative number indicates younger and a positive number indicates older. A negative change from Baseline indicates an improvement. (NCT02438813)
Timeframe: Baseline (Day 1) to End of Treatment Visit (Up to 18 Months)

,,,,,
Interventionyears (Mean)
BaselineChange to EOT Visit
Deoxycholic Acid (ATX-101)-1.4-1.5
Energy Devices-0.5-0.6
Laser Liposuction3.0-10.0
Not Elected Treatment-1.2-1.6
Other Treatments-0.6-0.8
Surgical0.5-5.6

[back to top]

Change From Baseline in the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The CR-SMFRS is based on the investigator's clinical evaluation of the participant's chin and neck area using a 5-point ordinal scale (0 to 4) with 0=Absent Submental Convexity: no localized submental fat evident; 1=Mild Submental Convexity: minimal, localized submental fat; 2=Moderate Submental Convexity: prominent, localized submental fat; 3=Severe Submental Convexity; a marked amount of chin fat; and 4=Extreme Submental Convexity: marked, localized submental fat. A negative change from Baseline indicates improvement. (NCT02438813)
Timeframe: Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment (EOT) Visit (Up to 18 Months)

,,,,,
Interventionscore on a scale (Mean)
BaselineChange to Follow-up VisitChange to EOT Visit
Deoxycholic Acid (ATX-101)2.0-0.4-0.8
Energy Devices1.7-0.7-0.9
Laser Liposuction3.2-2.0-2.5
Not Elected Treatment2.0-0.5-0.8
Other Treatments1.8-0.4-0.2
Surgical2.7-1.6-2.1

[back to top]

Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

"The PR-SMFRS is based on the participant's response to the question How much fat do you have under your chin right now? answered on a 5-point ordinal scale (0 to 4) with 0=No chin fat at all, 1=A slight amount of chin fat, 2=A moderate amount of chin fat, 3=A large amount of chin fat, and 4=A very large amount of chin fat. A negative change from Baseline indicates improvement." (NCT02438813)
Timeframe: Baseline (Day 1) to the Follow-up Visit (Up to 9 Months) and Baseline to End of Treatment Visit (Up to 18 Months)

,,,,,
Interventionscore on a scale (Mean)
BaselineChange to Follow-up VisitChange to EOT Visit
Deoxycholic Acid (ATX-101)2.0-0.3-0.7
Energy Devices1.8-0.5-0.8
Laser Liposuction3.2-2.2-2.0
Not Elected Treatment2.0-0.4-0.7
Other Treatments2.0-0.8-0.5
Surgical2.5-1.5-1.6

[back to top]

Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event is any undesirable medical occurrence or worsening of an existing condition that occurs after SMF reduction treatment, irrespective of whether the event is considered treatment related. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving treatment. (NCT02438813)
Timeframe: Up to 19 Months

Interventionpercentage of participants (Number)
Deoxycholic Acid (ATX-101)13.2
Surgical8.7
Laser Liposuction20.0
Energy Devices5.2
Other Treatments22.2

[back to top]

The Proportion of Subjects for Whom a 2-grade Improvement Was Recorded Using the CR-SMFRS From Baseline to Final Follow-uo Visit.

The CR-SMFRS is a 5-point scale ranging from 0 to 5, with '0' = Absent Submental Convexity: no localized submental fat evident, '1' = Mild Submental Convexity: minimal localized submental fat, '2'= Moderate Submental Convexity: prominent, localized submental fat, '3' = Severe Submental Convexity: Marked, localized submental fat, '4' = Extreme Submental Convexity. The investigator performed the evaluation of each subject, including palpation of the neck and chin area; oblique anterior and profile views of the chin and neck; and observation of pronation, supination and lateral movement of the head. The score was determined during a live assessment while the subject's head was in the Frankfort plane posture and was recorded as a whole number. (NCT03510598)
Timeframe: Baseline and 12-week post-treatment follow-up visit.

InterventionParticipants (Count of Participants)
Treatment for Submental Fat Reduction Using Zeltiq CoolSculpting System Followed by Kybella10

[back to top]

The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When Compared to the Baseline Grade.

The CR-SMFRS is a 5-point scale ranging from 0 to 5, with '0' = Absent Submental Convexity: no localized submental fat evident, '1' = Mild Submental Convexity: minimal localized submental fat, '2'= Moderate Submental Convexity: prominent, localized submental fat, '3' = Severe Submental Convexity: Marked, localized submental fat, '4' = Extreme Submental Convexity. The investigator performed the evaluation of each subject, including palpation of the neck and chin area; oblique anterior and profile views of the chin and neck; and observation of pronation, supination and lateral movement of the head. The score was determined during a live assessment while the subject's head was in the Frankfort plane posture and was recorded as a whole number. (NCT03510598)
Timeframe: Baseline and 12-week post-treatment follow-up visit.

InterventionParticipants (Count of Participants)
Treatment for Submental Fat Reduction Using Zeltiq CoolSculpting System Followed by Kybella14

[back to top] [back to top]

Subject Satisfaction as Measured by a Comparison of Baseline and 12-weeks Post-final Treatment of Completed Subject Self-Rating Scales (SSRS).

"The SSRS is a 7-point scale with 0 = extremely dissatisfied 1= dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly dissatisfied, 5 = satisfied, and 6 = extremely satisfied. The percentage of subjects reporting slightly satisfied, satisfied or extremely satisfied is presented." (NCT03510598)
Timeframe: Baseline and 12-weeks post- final treatment visit.

Interventionpercent of participants (Mean)
Treatment for Submental Fat Reduction Using Zeltiq CoolSculpting System Followed by Kybella71.4

[back to top]

Change in Submental Fat Layer Thickness as Measured by Ultrasound.

Change in the fat layer thickness will be calculated by comparison of pre-treatment and 12 week post-final treatment ultrasound measurements taken in the area treated with the device. The Sponsor's standardized techniques for obtaining ultrasound imaging will be used. Overall fat layer thickness changes will be normalized for each subject by subtracting the change in the pre-treatment area from the change in treated area to remove the influence of weight variations. This result is considered the treatment effect. Results indicate the fat layer reduction in centimeters. (NCT03510598)
Timeframe: 12-week post-treatment follow-up visit.

Interventioncentimeters (Mean)
Treatment for Submental Fat Reduction Using Zeltiq CoolSculpting System Followed by Kybella0.02

[back to top]

Number of Participants With Adverse Events

"Any adverse event (AE) ascertained by patient report or physician evaluation~One or more serious adverse events (SAE) as defined by CTCAEv4~Adverse events leading to study drug discontinuation." (NCT04054011)
Timeframe: Baseline to 12 weeks after last treatment

Interventionparticipants (Number)
ransient subcutaneous nodulesinjection-site urticariaTemporary numbness
Deoxycholic Acid080102

[back to top]

Percent Accuracy by Three Blinded Physicians in Correctly Identifying Before-and-after Photographs

3 blinded physicians identified the before and after photos and the percentage number was 83% for percent accuracy of the results. The percent accuracy was calculated for the entire Arm/Group rather than for each participant (NCT04054011)
Timeframe: 12 weeks

Interventionpercent accuracy of post treatment photo (Number)
Deoxycholic Acid83

[back to top]

Change in Thigh Gap

"Thigh gap, measured with a handheld soft ruler, was defined as the horizontal distance between baseline sites of maximum bulge, with feet at standardized distance apart." (NCT04054011)
Timeframe: 12 weeks

Interventioncentimeters (Mean)
Deoxycholic Acid ?Placebo1.6

[back to top]

Upper Inner Thigh Skin Fold Thickness Change

change in upper inner thigh skin fold thickness as measured by body fat calipers (NCT04054011)
Timeframe: Baseline to 12 weeks after last treatment

Interventionmm (Mean)
average change from baselineat 4 weekaverage change from baseline at 12 week
Deoxycholic Acid-7.3-8.8

[back to top]

Thigh Circumference Change

change in thigh circumference as measured by tape measure (NCT04054011)
Timeframe: Baseline to 12 weeks after last treatment

Interventioncm (Mean)
average change from baseline at 4 weekaverage change from baseline at 12 week
Deoxycholic Acid-1.8-2.2

[back to top]